

CITATION REPORT

List of articles citing

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

DOI: 10.1016/s1470-2045(13)70604-1
Lancet Oncology, The, 2014, 15, 213-22.

Source: <https://exaly.com/paper-pdf/58827462/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1606	Mesenchymal stem cells derived from bone marrow of diabetic patients portrait unique markers influenced by the diabetic microenvironment. 2009 , 6, 260-70		43
1605	Afatinib: first global approval. 2013 , 73, 1503-15		167
1604	Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. 2014 , 47, 929-39		77
1603	Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. 2014 , 7, 1689-704		54
1602	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. 2014 , 9, e107161		110
1601	Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. 2014 , 4, 297-310		13
1600	EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data. 2014 , 7, 2075-84		30
1599	EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. 2014 , 8, 1595-611		31
1598	Targeted treatment of mutated -expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. 2014 , 5, 73-79		1
1597	50 Years of progress in the systemic therapy of non-small cell lung cancer. 2014 , 177-89		75
1596	Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study. 2014 , 22, 1010-8		29
1595	Strategies for cancer prevention in IndiaâCatching the âw hanging fruitsâ 2014 , 2, 105-106		3
1594	Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. 2014 , 74, 661-5		20
1593	Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status. 2014 , 31, 287		17
1592	ErbB-Blocker beim EGFR-mutierten NSCLC. 2014 , 17, 24-24		
1591	Management of NSCLC: focus on crizotinib. 2014 , 15, 2587-97		13
1590	Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. 2014 , 21, 329-36		54

1589	Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs. 2014 , 4, 238	50
1588	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. 2014 , 4, 258	2
1587	Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. 2014 , 4, 190	39
1586	Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. 2014 , 4, 233	11
1585	[Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]. 2014 , 139, 2096-100	6
1584	Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. 2014 , 105, 1040-8	12
1583	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. 2014 , 15, 2693-708	18
1582	Dacomitinib: another option for EGFR-mutant lung cancer?. <i>Lancet Oncology, The</i> , 2014 , 15, 1408-1409	21.7 5
1581	Pharmacotherapy targeting the EGFR oncogene in NSCLC. 2014 , 15, 2293-305	16
1580	[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker]. 2014 , 101, 647-52	3
1579	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. 2015 , 17, 430-9	78
1578	EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. 2014 , 4, 350	9
1577	Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. 2014 , 106,	7
1576	Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. 2014 , 4, 244	49
1575	Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. 2014 , 4, 256	13
1574	Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. 2014 , 23, 356-66	105
1573	Afatinib for lung cancer: let there be light?. <i>Lancet Oncology, The</i> , 2014 , 15, 133-4	21.7 4
1572	Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome. 2014 , 40, 723-9	17

1571	Afatinib for the treatment of advanced non-small-cell lung cancer. 2014 , 15, 889-903	19
1570	Protein kinase inhibitors to treat non-small-cell lung cancer. 2014 , 15, 1203-13	16
1569	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1433-1441	21.7 92
1568	Guide to Targeted Therapies: EGFR mutations in NSCLC. 2014 ,	
1567	Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. 2014 , 52, 330-8	12
1566	Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. 2014 , 15, 411-417.e4	28
1565	Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. 2014 , 15, 441-7	30
1564	Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. 2014 , 25, 2385-2391	46
1563	Update on systemic therapy of advanced non-small-cell lung cancer. 2014 , 14, 1189-203	19
1562	Cancer care and research in India: what does it mean to Nepal?. <i>Lancet Oncology, The</i> , 2014 , 15, e299-300	21.7 3
1561	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. 2014 , 40, 917-26	103
1560	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 1236-44	21.7 524
1559	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. 2014 , 31, 78	4
1558	Neue Substanzen für die Therapie solider Tumoren. 2014 , 29, 300-304	
1557	Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. 2014 , 74, 267-75	31
1556	Understanding lung cancer molecular subtypes. 2014 , 11, 441-453	1
1555	Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. 2014 , 39, 465-74	110
1554	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. 2014 , 15, 173-81	50

1553	Afatinib in NSCLC harbouring EGFR mutations. <i>Lancet Oncology, The</i> , 2014 , 15, e148-9	21.7	6
1552	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. 2014 , 40, 990-1004		60
1551	Review of the current targeted therapies for non-small-cell lung cancer. 2014 , 5, 576-87		50
1550	The Role of ERBB Family Blockade in NSCLC. 2014 , 2, 51-58		
1549	Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. 2014 , 3, 477-489		
1548	The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. 2015 , 10, 903-9		26
1547	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. 2015 , 10, 883-9		45
1546	Towards manageable toxicities from targeted lung cancer treatment. 2015 , 4, 279-287		
1545	Novel targeted agents for the treatment of lung cancer in China. 2015 , 121 Suppl 17, 3089-96		7
1544	Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. 2015 , 20, 199-208		3
1543	Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. 2015 , 121 Suppl 17, 3069-79		41
1542	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. 2015 , 278, 545-70		38
1541	Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. 2015 , 5, 24		15
1540	Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients. 2015 , 5, 15355		5
1539	A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. 2014 , 4, 7268		24
1538	Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report. 2015 , 3, 889-891		0
1537	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. 2015 , 10, 33-40		7
1536	Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification. 2015 , 47, 320-8		16

1535	Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. 2015 , 10, 1553-9	109
1534	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. 2015 , 34, 310-9	8
1533	Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. 2015 , 8, 54	46
1532	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. 2015 , 10, 55-68	22
1531	Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report. 2015 , 101, e64-6	1
1530	From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. 2015 , 21, 413-24	2
1529	Adequacy of Malignant Pleural Effusion for Epidermal Growth Factor Receptor Mutation Analysis Using the Pyrosequencing Method. 2015 , 2, 237399751561658	2
1528	Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). 2015 , 121, 2253-61	19
1527	Long progression-free survival with afatinib in a patient with heavily pretreated lung adenocarcinoma without common activating EGFR mutations. 2015 , 4, 263-269	0
1526	Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer. 2015 , 26, 995-1003	12
1525	The Evolution of Therapies in Non-Small Cell Lung Cancer. 2015 , 7, 1815-46	81
1524	An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib. 2015 , 8, 1351-4	6
1523	Afatinib for the treatment of metastatic non-small cell lung cancer. 2015 , 7, 75-82	26
1522	miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. 2015 , 9, 569	11
1521	Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?. 2015 , 9, 5641-53	21
1520	Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review. 2015 , 10, e0121211	14
1519	Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. 2015 , 41, 365-75	19
1518	Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection. 2015 , 2015, 215128	18

1517	Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer. 2015 , 2015, 672759		34
1516	A Phase III Study Comparing Gefitinib and Inserted Platinum-doublet Chemotherapy with Gefitinib as a First-line Treatment for Patients with Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Activating Mutations. 2015 , 55, 879-884		
1515	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. 2015 , 6, 26814-25		117
1514	Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. 2015 , 11, 1109-22		16
1513	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology, The</i> , 2015 , 16, 830-8	21.7	551
1512	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. 2015 , 11, 1611-23		70
1511	EGFR mutations and EGFR tyrosine kinase inhibitors. <i>Lancet Oncology, The</i> , 2015 , 16, 746-8	21.7	3
1510	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. 2015 , 89, 1227-40		28
1509	Crizotinib in the management of advanced-stage non-small-cell lung cancer. 2015 , 11, 735-45		10
1508	Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. 2015 , 9, 242-50		35
1507	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. 2015 , 21, 3913-23		256
1506	Targeting EGFR in lung cancer: Lessons learned and future perspectives. 2015 , 45, 67-73		34
1505	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. 2015 , 11, 2175-91		4
1504	Experience with erlotinib in the treatment of non-small cell lung cancer. 2015 , 9, 146-63		19
1503	Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study. 2015 , 10, 1370-1374		21
1502	Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2015 , 94, e2239		5
1501	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. 2015 , 106, 1202-11		74
1500	Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations. 2015 , 46, 19-21		

1499	Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. 2015 , 76, 739-50	13
1498	Cancers bronchiques non ^ petites cellules mutés ou rarrangés : de la premiere à la hñme ligne. 2015 , 7, 497-505	
1497	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. 2015 , 10, 1396-403	57
1496	Une << population spciale >> : les sujets gš. 2015 , 7, 524-530	
1495	Chimiothapie pfiopfatoire du cancer bronchique non ^ petites cellules (CBNPC) vue par le chirurgien. 2015 , 7, 367-374	
1494	Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer. 2015 , 148, 1063-1072	15
1493	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. 2015 , 96, 206-19	20
1492	EGFR T790M resistance mutation in non small-cell lung carcinoma. 2015 , 444, 81-5	57
1491	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. 2015 , 24, 673-87	7
1490	Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. 2015 , 88, 63-9	60
1489	Interstitial lung disease arising from erlotinib treatment in a Caucasian patient. 2015 , 16, e1-3	7
1488	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. 2015 , 16, 280-96	150
1487	Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. 2015 , 16, 252-61	23
1486	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2015 , 16, 141-51	21.7 1081
1485	The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. 2015 , 20, 307-15	39
1484	What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. 2015 , 11, 153-67	20
1483	Molecular histology of lung cancer: from targets to treatments. 2015 , 41, 361-75	117
1482	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 2015 , 8, 461-77	26

1481	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. 2015 , 21, 5305-13		126
1480	Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. 2015 , 89, 337-42		33
1479	Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. 2015 , 16, 1434-7		5
1478	Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients. 2015 , 17, 727-36		18
1477	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). 2015 , 26, 1877-1883		308
1476	TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung Cancer. 2015 , 21, 5173-5180		34
1475	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 897-907	21.7	314
1474	Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. 2015 , 22, e183-215		50
1473	EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models. 2015 , 32, 205		20
1472	Biomarker testing in non-small cell lung cancer: a clinician's perspective. 2015 , 139, 448-50		5
1471	Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. 2015 , 75, 1335-48		77
1470	Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. 2015 , 29, 167-83		48
1469	Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. 2015 , 90, 65-70		36
1468	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. 2015 , 26, 1883-1889		480
1467	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. 2015 , 21, 3196-203		341
1466	Emerging treatment for advanced lung cancer with EGFR mutation. 2015 , 20, 597-612		17
1465	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 990-8	21.7	291
1464	Chemotherapy for lung cancer: still alive!. 2015 , 45, 609-10		1

1463	Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. 2015 , 20, 967-74	53
1462	Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany. 2015 , 33, 1215-28	21
1461	Management of egfr tki-induced dermatologic adverse events. 2015 , 22, 123-32	50
1460	[Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis]. 2015 , 102, 360-6	3
1459	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. 2015 , 88, 74-9	127
1458	Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. 2015 , 88, 282-8	39
1457	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. 2015 , 20, 400-10	89
1456	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. 2015 , 6, 224-6	0
1455	Traitements ciblés et immunothérapie : quel apport en pratique ?. 2015 , 7, 51-62	
1454	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 2015 , 16, 325-33	55
1453	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. 2015 , 27, 36-48	7
1452	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. 2015 , 33, 1958-65	211
1451	The epidermal growth factor receptor (EGFR) in lung cancer. 2015 , 3, 1	26
1450	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. 2015 , 41, 401-11	33
1449	Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. 2015 , 14, 97-110	5
1448	Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. 2015 , 11, 1259-74	10
1447	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. 2015 , 1, 149-57	193
1446	Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer. 2015 , 34, 173-82	6

1445	Emerging paradigms in targeted treatments for Asian patients with NSCLC. 2015 , 16, 1167-76		15
1444	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. 2015 , 9, 255-68		21
1443	Caractérisation de populations tumorales dans les cancers bronchiques non ^petites cellules en TEP au FDG en fonction de critères anatomopathologiques et génétiques. 2015 , 39, 165-172		
1442	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. 2015 , 10, S1-63		102
1441	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. <i>Lancet Oncology, The</i> , 2015 , 16, e165-72	21.7	477
1440	Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. 2015 , 10, 665-72		22
1439	Organoid development in cancer genome discovery. 2015 , 30, 42-8		40
1438	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. 2015 , 27, 94-101		102
1437	Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. 2015 , 11, 1245-57		44
1436	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). 2015 , 20, 370-8		92
1435	Management of EGFR mutated nonsmall cell lung carcinoma patients. 2015 , 45, 1132-41		25
1434	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. 2015 , 15, 1327-36		9
1433	Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. 2015 , 15, 1427-40		32
1432	Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. 2015 , 90, 307-13		16
1431	Current challenges of lung cancer care in an aging population. 2015 , 15, 1419-29		8
1430	Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. 2015 , 20, 1167-74		44
1429	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. 2015 , 113, 1413-20		14
1428	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. 2015 , 90, 1-7		10

1427	[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC]. 2015 , 102, S27-33	0
1426	Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. 2015 , 4, 1621-32	32
1425	Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress. 2015 , 16, 51	8
1424	Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. 2015 , 32, 907-16	8
1423	Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. 2015 , 15, 885-91	7
1422	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. 2015 , 113, 1519-28	70
1421	Management of pulmonary toxicity associated with targeted anticancer therapies. 2015 , 11, 1695-707	9
1420	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. 2015 , 11, 267-77	12
1419	Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. 2015 , 58, 8200-15	79
1418	A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. 2015 , 51, 2275-84	19
1417	Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. 2015 , 11, 2525-40	17
1416	Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States. 2015 , 18, 774-82	47
1415	Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. 2015 , 89, 287-93	25
1414	EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. 2015 , 76, 835-41	35
1413	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. 2015 , 90, 261-6	4
1412	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. 2015 , 15, 1553-66	16
1411	Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers. 2015 , 90, 205-11	5
1410	Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. 2015 , 27, 40-51	38

1409	Pharmacogenomic biomarkers for personalized cancer treatment. 2015 , 277, 201-217	38
1408	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. 2015 , 12, 197-212	139
1407	[Targeted therapies in non-small cell lung cancer in 2014]. 2015 , 32, 182-92	8
1406	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. 2015 , 112, 95-102	407
1405	New Therapeutic Strategies in Lung Cancers. 2015 ,	0
1404	Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. 2016 , 7, 69450-69465	42
1403	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. 2016 , 7, 1066-75	120
1402	Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. 2016 , 9, 4301-5	16
1401	Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. 2016 , 9, 929-35	10
1400	Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). 2016 , 7, 58492-58499	61
1399	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 2016 , 7, 6984-93	115
1398	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17	18
1397	Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. 2017 , 9, 31-38	13
1396	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. 2016 , 7, 3884-96	25
1395	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. 2016 , 5, 563-578	28
1394	Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?. 2016 , 8, E217-20	5
1393	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. 2016 , 5, 446-9	5
1392	Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. 2016 , 5, 401-12	38

1391	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. 2016 , 5, 628-636	12
1390	Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. 2016 , 8, E1517-E1519	1
1389	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. 2016 , 9, 5461-73	32
1388	An update on clinical oncology for the non-oncologist. 2016 , 14, 294-9	
1387	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. 2016 , 6, 112	20
1386	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. 2016 , 11, e0152079	32
1385	Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. 2016 , 12, 807-16	7
1384	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. 2016 , 9, 3711-26	71
1383	Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis. 2016 , 9, 1135-43	16
1382	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. 2016 , 6, 1232-43	28
1381	The Current Situation and Problems of Re-biopsy in Non-small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations. 2016 , 56, 331-336	
1380	Spécificité de la prise en charge du CBNPC chez les sujets âgés. 2016 , 18, 401-408	1
1379	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. 2016 , 28, 115-21	18
1378	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. 2016 , 17, 1693-701	5
1377	Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. 2016 , 30, 1150-1154	28
1376	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. 2016 , CD010383	98
1375	The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. 2016 , 61, 179-89	5
1374	Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization. 2016 , 9, 62-7	15

1373	Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. 2016 , 11, 68-77	7
1372	Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. 2016 , 1, e000083	45
1371	Emerging therapeutic agents for lung cancer. 2016 , 9, 138	65
1370	Les cancers bronchiques non ^petites cellules EGFR-mut\$. 2016 , 8, 373-381	
1369	Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. 2016 , 11, 619-629	11
1368	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. 2016 , 15, 837-51	10
1367	Genotyping of EGFR Mutations from Bronchial Cytological Specimens in Slovakian Lung Cancer Patients. 2016 , 934, 49-61	
1366	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. 2016 , 11, 946-63	145
1365	S768I Mutation in EGFR in Patients with Lung Cancer. 2016 , 11, 1798-801	41
1364	Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma. 2016 , 11, 1574-85	20
1363	Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC. 2016 , 15, 1988-97	12
1362	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2016 , 17, 461-465	27
1361	Safety of gefitinib in non-small cell lung cancer treatment. 2016 , 15, 993-1000	5
1360	Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. 2016 , 10, 256-64	12
1359	Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?. 2016 , 34, 774-6	
1358	Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. 2016 , 140, 245-8	9
1357	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology, The</i> , 2016 , 17, 577-89	21.7 691
1356	Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. 2016 , 90, 289-98	7

1355	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. 2016 , 76, 831-40	11
1354	The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients. 2016 , 22, 755-61	2
1353	What's hot in lung cancer. 2016 , 37, 79-85	
1352	Medikamentöse Behandlung des Lungenkarzinoms – Grundlagen und neue Säulen der Therapie. 2016 , 45, 140-147	
1351	Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. 2016 , 96, 56-62	26
1350	[Targeted therapy and precision medicine : More than just words in the treatment of lung cancer]. 2016 , 57, 1243-1249	2
1349	Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. 2016 , 99, 1-3	11
1348	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. 2016 , 27, 2103-2110	128
1347	Resisting Resistance: Targeted Therapies in Lung Cancer. 2016 , 2, 350-364	94
1346	[Osimertinib (Tagrisso): Activity, indication and modality of use in non-small cell lung cancer]. 2016 , 103, 815-821	0
1345	[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma]. 2016 , 146 Suppl 1, 2-6	3
1344	[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment]. 2016 , 146 Suppl 1, 25-9	3
1343	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. 2016 , 78, 941-947	5
1342	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. 2016 , 17, 2253-2266	22
1341	[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib]. 2016 , 146 Suppl 1, 30-5	1
1340	Metastatic Lung Cancer: Emerging Therapeutic Strategies. 2016 , 37, 736-749	1
1339	EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. 2016 , 37, 887-903	65
1338	Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan. 2016 , 46, 1135-1142	1

1337	Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. 2016 , 107, 1134-40	61
1336	Pulmonary Dysfunction and Disease. 2016 ,	
1335	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. 2016 , 34, 3258-66	107
1334	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. 2016 , 107, 45-52	58
1333	Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma. 2016 , 102, 1821-1828	7
1332	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. 2016 , 107, 1179-86	210
1331	Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. 2016 , 11, 2022-2026	60
1330	Mechanisms of resistance to EGFR-targeted drugs: lung cancer. 2016 , 1, e000060	229
1329	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. 2016 , 11, 2066-2081	40
1328	Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial. 2016 , 7, 663-669	17
1327	New and emerging targeted treatments in advanced non-small-cell lung cancer. 2016 , 388, 1012-24	299
1326	Management of Lung Cancer in the Elderly. 2016 , 170, 251-84	8
1325	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. 2016 , 11, 1387-96	6
1324	Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. 2016 , 12, 2741-2753	8
1323	Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. 2016 , 34, 797-799	8
1322	Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?. 2016 , 17, 54	13
1321	The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. 2016 , 5, 1244	10
1320	Targeted Therapies for Lung Cancer. 2016 , 170, 165-82	10

1319	Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. 2016 , 11, 825-835	23
1318	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. 2016 , 115, 1504-1512	38
1317	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. 2016 , 9, 1283-1288	1
1316	The safety of afatinib for the treatment of non-small cell lung cancer. 2016 , 15, 1563-1572	13
1315	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. 2016 , 9, 86	31
1314	Selective Covalent Targeting of Anti-Apoptotic BCL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. 2016 , 23, 1123-1134	46
1313	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. 2016 , 33, 97	30
1312	[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation]. 2016 , 146 Suppl 1, 12-8	
1311	Profile of the theascreen [®] EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. 2016 , 16, 1251-1257	13
1310	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 2016 , 1, e000088	69
1309	Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies. 2016 , 12, 2117-26	7
1308	Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. 2016 , 6, 36458	60
1307	Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. 2016 , 7, 543-548	7
1306	Resistance to Tyrosine Kinase Inhibitors. 2016 ,	1
1305	Kinetics and Thermodynamics of Reversible Thiol Additions to Mono- and Diactivated Michael Acceptors: Implications for the Design of Drugs That Bind Covalently to Cysteines. 2016 , 81, 11726-11733	71
1304	Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. 2016 , 6, 31636	3
1303	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016 , 27, v1-v27	590
1302	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer. 2016 , 91 Suppl 1, 26-34	10

1301	Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. 2016 , 16, 868	12
1300	The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations. 2016 , 95, e3991	3
1299	Best Practices in Treatment Selection for Patients With Advanced NSCLC. 2016 , 23, 2-14	5
1298	Mutations in Latinos From the United States and Latin America. 2016 , 2, 259-267	8
1297	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 984-993	21.7 498
1296	Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer. 2016 , 16, 354	6
1295	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. 2016 , 5, 79-90	1
1294	Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. 2016 , 77, 1005-9	12
1293	Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation. 2016 , 193, 753-66	14
1292	Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials. 2016 , 17, 91-4	3
1291	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. 2016 , 8, 176-87	22
1290	Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine. 2016 , 2, 1-3	8
1289	Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. 2016 , 12, 355-72	13
1288	Effect of renal function on pemetrexed-induced haematotoxicity. 2016 , 78, 183-9	6
1287	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). 2016 , 46, 25-37	26
1286	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 357-366	21.7 97
1285	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. 2016 , 48, 937-44	52
1284	EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. 2016 , 17, 320-7	26

1283	Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer. 2016 , 127, 525-33	9
1282	Targeted therapy in cancer. 2016 , 44, 34-38	18
1281	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. 2016 , 91, 36-40	29
1280	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. 2016 , 27, 417-23	101
1279	Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer. 2016 , 22, 2167-76	13
1278	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. 2016 , 10, 113-29	97
1277	Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. 2016 , 72, 1-11	42
1276	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. 2016 , 8, 479-88	105
1275	Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. 2016 , 94, 46-53	48
1274	Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis. 2016 , 7, 406-14	18
1273	Skin problems and EGFR-tyrosine kinase inhibitor. 2016 , 46, 291-8	59
1272	Diamond: immunohistochemistry versus sequencing in EGFR analysis of lung adenocarcinomas. 2016 , 69, 440-7	13
1271	Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature. 2016 , 11, 174-86	63
1270	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. 2016 , 36, 63-72	3
1269	Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. 2016 , 12, 815-25	3
1268	Cancer research: in need of introspection. <i>Lancet Oncology, The</i> , 2016 , 17, 140-141	21.7 2
1267	Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). 2016 , 28, 50-8	7
1266	therascreen [®] EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer. 2016 , 20, 191-8	11

1265	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. 2016 , 11, 380-90	240
1264	Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations. 2016 , 11, 281-3	1
1263	Being molecular in the molecular age. 2016 , 27, 367-8	
1262	Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions. 2016 , 17, 989-93	17
1261	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. 2016 , 11, 556-65	176
1260	Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. 2016 , 10, 547-56	8
1259	Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. 2016 , 17, 855-63	17
1258	Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo. 2016 , 469, 1075-82	63
1257	Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis. 2016 , 10, 223-34	3
1256	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. 2016 , 9, 143-55	1
1255	Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. 2016 , 18, 576-81	6
1254	Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. 2016 , 97, 143-51	22
1253	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. 2016 , 22, 461-76	21
1252	Pyogenic granuloma caused by afatinib: Case report and review of the literature. 2017 , 58, 61-62	5
1251	Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. 2017 , 107, 100-107	94
1250	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. 2017 , 116, 568-574	120
1249	The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. 2017 , 19, 1	38
1248	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. 2017 , 104, 119-125	31

1247	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. 2017 , 18, 281-285	30
1246	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. 2017 , 18, 151-163	9
1245	Sex Differences in Hazard Ratio During Drug Treatment of Non-small-cell Lung Cancer in Major Clinical Trials: A Focused Data Review and Meta-analysis. 2017 , 39, 34-54	5
1244	Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. 2017 , 19, 4	12
1243	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. 2017 , 174, 1-21	87
1242	Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. 2017 , 11, 171-180	7
1241	The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. 2017 , 7, 40374	32
1240	Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. 2017 , 13, 304-313	10
1239	Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. 2017 , 22, 61-69	20
1238	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. 2017 , 35, 1288-1296	363
1237	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. 2017 , 25, 1713-1739	82
1236	Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature. 2017 , 18, 354-363	34
1235	Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung. 2017 , 6, 38-41	2
1234	EGFR inhibition in NSCLC: New findings and opened questions?. 2017 , 112, 126-135	20
1233	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). 2017 , 13, 87-103	29
1232	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. 2017 , 108, 75-82	24
1231	The changing landscape of clinical trial and approval processes in China. 2017 , 14, 577-583	22
1230	Cancer of the Lung. 2017 , 1-30	0

1229	Surrogate endpoints for overall survival in lung cancer trials: a review. 2017 , 17, 447-454	10
1228	Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day. 2017 , 8, 312-319	7
1227	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. 2017 , 22, 700-708	9
1226	Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. 2017 , 12, 1061-1070	178
1225	Uncommon EGFR mutations in advanced non-small cell lung cancer. 2017 , 109, 137-144	84
1224	Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm. 2017 , 31, 83-99	9
1223	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. 2017 , 31, 31-44	6
1222	Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. 2017 , 17, 143-155	19
1221	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. 2017 , 12, 563-569	50
1220	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. 2017 , 22, 1075-1083	19
1219	Mechanisms of Molecular Carcinogenesis – Volume 2. 2017 ,	1
1218	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. 2017 , 17, 281	21
1217	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. 2017 , 12, 1247-1256	40
1216	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. 2017 , 12, 1376-1387	29
1215	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. 2017 , 12, 1368-1375	57
1214	Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare gene mutations. 2017 , 13, 4433-4444	33
1213	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. 2017 , 109,	136
1212	PET microdosing of CNS drugs. 2017 , 5, 291-298	1

1211	Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. 2017 , 116, 413-423	14
1210	Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC. 2017 , 11, 10-16	1
1209	Determination of AZD3759 in rat plasma and brain tissue by LC-MS/MS and its application in pharmacokinetic and brain distribution studies. 2017 , 140, 362-366	4
1208	Targeted Treatment of Brain Metastases. 2017 , 17, 37	24
1207	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. 2017 , 108, 154-160	13
1206	Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. 2017 , 16, 891-910	25
1205	Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition. 2017 , 77, 3013-3026	32
1204	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. 2017 , 6, 3-6	19
1203	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. 2017 , 9, 201-216	22
1202	Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. 2017 , 6, 517-523	12
1201	Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. 2017 , 55, 181-183	2
1200	Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. 2017 , 106, 138-144	14
1199	Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. 2017 , 37, 581-585	1
1198	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. 2017 , 376, 629-640	1811
1197	A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. 2017 , 6, 154-162	67
1196	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. 2017 , 12, 633-643	82
1195	Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. 2017 , 12, 612-623	115
1194	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. 2017 , 116, 175-185	61

1193	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. 2017 , 79, 209-213		6
1192	New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. 2017 , 11, 51-55		13
1191	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. 2017 , 35, 243-252		15
1190	Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy. 2017 , 13, e531-e533		6
1189	Balancing Equity and Advancement: The Role of Health Technology Assessment in Radiotherapy Resource Allocation. 2017 , 29, 93-98		5
1188	Predictors of mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. 2017 , 14, 5611-5618		6
1187	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1454-1466	21.7	559
1186	Gefitinib: an âphanâdrug for non-small cell lung cancer. 2017 , 5, 899-906		1
1185	Direct surface grafting of mesoporous silica nanoparticles with phospholipid choline-containing copolymers through chain transfer free radical polymerization and their controlled drug delivery. 2017 , 508, 396-404		25
1184	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. 2017 , 17, 933-942		3
1183	Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis. 2017 , 7, 11528		
1182	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. 2017 , 112, 195-199		7
1181	External quality assessment for EGFR mutations in Italy: improvements in performances over the time. 2017 , 2, e000160		8
1180	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. 2017 , 35, 1195-1209		14
1179	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. 2017 , 113, 51-58		12
1178	Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. 2017 , 7, 8483		3
1177	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. 2017 , 34, 175		4
1176	Case series on the association between blood levels and side effects of afatinib maleate. 2017 , 80, 545-553		2

1175	Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. 2017 , 5, 707-716	114
1174	Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. 2017 , 117, 38-47	66
1173	Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. 2017 , 59, 117-122	38
1172	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. 2017 , 83, 266-278	16
1171	Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report. 2017 , 96, e6221	4
1170	Prädiktive molekulare Marker als therapeutische Weichensteller beim nichtkleinzelligen Lungenkarzinom. 2017 , 32, 307-311	
1169	TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. 2017 , 14, 2153-2164	18
1168	Lung cancer as a cardiotoxic state: a review. 2017 , 34, 159	7
1167	Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. 2017 , 7, 6595	20
1166	Personalised medicine for nonsmall cell lung cancer. 2017 , 26,	28
1165	A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. 2017 , 114, 96-102	105
1164	Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. 2017 , 13, 1281-1288	3
1163	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. 2017 , 77, 4238-4246	69
1162	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. 2017 , 17, 779-786	24
1161	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. 2017 , 28, 270-277	296
1160	Efficacy and Safety Results of the Afatinib Expanded Access Program. 2017 , 5, 103-110	5
1159	Recent advances in targeted advanced lung cancer therapy in the elderly. 2017 , 17, 787-797	10
1158	Adverse kidney effects of epidermal growth factor receptor inhibitors. 2017 , 32, 1089-1097	30

1157	Osimertinib-related skin and mucosal adverse events. 2017 , 12, 53-55	0
1156	Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. 2017 , 18, e333-e340	11
1155	Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. 2017 , 22, 3-11	29
1154	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. 2017 , 17, 5-8	5
1153	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. 2017 , 25, 27-37	31
1152	Capilliposide from <i>Lysimachia capillipes</i> inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. 2017 , 38, 100-109	10
1151	Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients. 2017 , 103, 1594-1599	13
1150	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. 2017 , 70, 12-21	28
1149	Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer. 2017 , 140, 1945-1954	13
1148	Treatment of brain metastases in the modern genomic era. 2017 , 170, 64-72	32
1147	Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. 2017 , 23, 618-622	25
1146	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. 2017 , 18, 241-244	6
1145	Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. 2017 , 42, 461-469	12
1144	MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. 2017 , 62, 57-65	49
1143	Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. 2017 , 56, 235-250	81
1142	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. 2017 , 195, 663-673	16
1141	Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy. 2017 , 18, e35-e40	2
1140	First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner isâ€¦ 2017 , 29, e1-e4	3

1139	Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. 2017 , 28, 136-141	53
1138	A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. 2017 , 79, 17-27	6
1137	Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis. 2017 , 18, 23-33.e1	11
1136	Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives. 2017 , 13, 201-204	2
1135	Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. 2017 , 18, 883-887	10
1134	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. 2017 , 12, 27-35	19
1133	EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. 2017 , 12, 585-590	28
1132	Les cancers bronchiques non ^ petites cellules EGFR-mutés. 2017 , 9, 213-223	
1131	Molecular Testing in Lung Cancer. 2017 , 287-303	1
1130	Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens. 2018 , 15, 1469-1474	6
1129	Métastases cérébrales des cancers bronchiques non ^ petites cellules (CBNPC). 2017 , 9, 271-287	
1128	Les rebiopsies : pourquoi ? Comment ?. 2017 , 9, 126-135	
1127	Prise en charge du CBNPC chez les sujets âgés. 2017 , 9, 299-307	
1126	Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. 2017 , 37, 864-872	2
1125	insight into EGFR treatment in patients with lung carcinoma and T790M mutations. 2017 , 13, 1735-1740	4
1124	Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. 2017 , 28, 2715-2724	48
1123	Liquid biopsy genotyping in lung cancer: ready for clinical utility?. 2017 , 8, 18590-18608	39
1122	Real-world experience of afatinib as a first-line therapy for advanced mutation-positive lung adenocarcinoma. 2017 , 8, 90430-90443	46

1121	Concurrent T790M and L858R mutations in treatment-naïve metastatic non-small-cell lung cancer: A therapeutic challenge â€” Current treatment strategies and promising therapies of the future in a nutshell. 2017 , 03, 087-091	
1120	Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test. 2017 , 03, 039-044	1
1119	Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. 2017 , 9, 2923-2934	15
1118	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. 2017 , 13, 223-236	15
1117	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. 2017 , 11, 787	24
1116	Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. 2017 , 10, 2473-2482	30
1115	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. 2017 , 10, 49-56	18
1114	Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors. 2017 , 6, 848-854	6
1113	The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. 2017 , 8, 1865-1871	5
1112	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. 2017 , 18,	70
1111	Afatinib. 2017 , 561-589	1
1110	Next-Generation Tyrosine Kinase Inhibitors for Treating -Mutant Lung Cancer beyond First Line. 2016 , 3, 76	52
1109	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. 2017 , 4, 39	17
1108	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. 2017 , 7, 38	12
1107	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. 2017 , 7, 50	21
1106	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. 2017 , 7, 97	10
1105	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. 2017 , 7, 113	38
1104	Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. 2017 , 7, 222	4

1103	Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma. 2017 , 2017, 9614938	4
1102	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. 2017 , 9, 655-668	8
1101	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. 2017 , 10, 2513-2526	25
1100	The liquid biopsy in lung cancer. 2016 , 7, 355-367	25
1099	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. 2017 , 9, 147-157	3
1098	Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. 2017 , 10, 4347-4354	2
1097	Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). 2017 , 10, 1757-1766	15
1096	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. 2017 , 5, S14	3
1095	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. 2017 , 8, 109-125	34
1094	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. 2017 , 8, 66491-66503	1
1093	Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients. 2017 , 25, 1601-1606	22
1092	Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. 2017 , 103, 325-337	6
1091	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. 2017 , 8, 410	80
1090	Addressing the challenges of applying precision oncology. 2017 , 1, 28	19
1089	The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. 2017 , 18, 82	24
1088	Inhibiting Kinases in the CNS. 2017 , 408-446	
1087	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. 2017 , 8, 90557-90578	29
1086	T790M: revealing the secrets of a gatekeeper. 2017 , 8, 147-159	13

1085	Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials. 2017 , 10, 1279-1284	4
1084	Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. 2017 , 10, 5107-5113	12
1083	EGFR G796D mutation mediates resistance to osimertinib. 2017 , 8, 49671-49679	66
1082	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. 2017 , 8, 75712-75726	66
1081	Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor. 2017 , 8, 180-187	19
1080	Cell free DNA analysis by SiRe next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. 2017 , 9, S1383-S1390	31
1079	Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. 2017 , 6, S21-S34	8
1078	Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. 2018 , 19, e361-e372	14
1077	Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common mutations. 2018 , 8, 421-428	4
1076	Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. 2018 , 65, 1-10	132
1075	Overview of current systemic management of EGFR-mutant NSCLC. 2018 , 29, i3-i9	100
1074	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in -Mutated Non-Small Cell Lung Cancer. 2018 , 17, 740-750	18
1073	Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer. 2018 , 14 Suppl 1, 4-6	1
1072	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. 2018 , 17, 38	253
1071	A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. 2018 , 35, 34	6
1070	Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples. 2018 , 109, 1177-1184	7
1069	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. 2018 , 36, 495-504	18
1068	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. 2018 , 3, e000344	60

1067	Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. 2018 , 120, 91-97	5
1066	The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. 2018 , 8, 5837	10
1065	EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. 2018 , 120, 82-87	8
1064	Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. 2018 , 23, 891-899	18
1063	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. 2018 , 123, 149-161	33
1062	Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. 2018 , 29, i10-i19	248
1061	Turning mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. 2018 , 10, 1758834017753338	38
1060	Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. 2018 , 15, 3726-3734	5
1059	Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?. 2018 , 14, 1117-1132	69
1058	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. 2018 , 118, 344-352	4
1057	Established, emerging and elusive molecular targets in the treatment of lung cancer. 2018 , 244, 565-577	11
1056	Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. 2018 , 13, 141-156	8
1055	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). 2018 , 24 Suppl 2, S41-S52	18
1054	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. 2018 , 117, 14-19	46
1053	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. 2018 , 18, 267-276	11
1052	Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. 2018 , 57, 211-220	12
1051	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. 2018 , 54, 10-17	
1050	Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. 2018 , 56, 179-183	5

1049	Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. 2018 , 11, 94-101	63
1048	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. 2018 , 118, 1599-1663	51
1047	High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. 2018 , 117, 1-6	34
1046	First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?. 2018 , 81, 443-453	8
1045	Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma. 2018 , 189, 48-59	7
1044	Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. 2018 , 13, 269-285	35
1043	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. 2018 , 119, 36-41	5
1042	Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive mutations. 2018 , 3, e000313	25
1041	Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). 2018 , 124, 2407-2414	9
1040	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. 2018 , 13, 792-800	15
1039	A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy. 2018 , 24, 3583-3592	90
1038	Afatinib in advanced NSCLC: a profile of its use. 2018 , 34, 89-98	10
1037	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. 2018 , 19, e465-e479	39
1036	Genomic Testing in Lung Cancer: Past, Present, and Future. 2018 , 16, 323-334	17
1035	Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?. 2018 , 18, 15-20	30
1034	Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. 2018 , 24, 379-388	29
1033	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. 2018 , 19, 42-50	5
1032	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. 2018 , 48, 37-44	8

1031	Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. 2018 , 20, 243-252	4
1030	Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. 2018 , 21, 192-200	22
1029	Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. 2018 , 210, 43-51	2
1028	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. 2018 , 54, 10-17	14
1027	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. 2018 , 13, 33-42	2
1026	Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. 2018 , 144, 165-171	5
1025	Management of Toxicities of Targeted Therapies. 2018 , 490-500.e3	0
1024	Lung cancer epigenetics: From knowledge to applications. 2018 , 51, 116-128	142
1023	Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. 2018 , 24, 994-1001	8
1022	Molecular Diagnosis and Targeting for Lung Cancer. 2018 , 1-32	
1021	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). 2018 , 11, 131-141	12
1020	Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. 2018 , 18, 81-89	19
1019	Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 2018 ,	0
1018	NSCLC Patients Harboring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. 2018 , 95, 169-176	9
1017	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. 2018 , 58, 485-493	9
1016	A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. 2018 , 115, 103-108	19
1015	Drug development in the era of precision medicine. 2018 , 17, 183-196	176
1014	Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice. 2018 , 19, 181-190	12

1013	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. 2018 , 115, 12-20	98
1012	Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer. 2018 , 19, 105-114	16
1011	Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations. 2018 , 9, 24237-24247	20
1010	Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. 2018 , 36, 2571-2574	6
1009	CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization. 2018 , 14, e612-e620	5
1008	Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. 2018 , 36, 1853-1860	22
1007	Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance. 2018 , 10, 1431-1439	8
1006	Lung cancer in never smokers-the East Asian experience. 2018 , 7, 450-463	47
1005	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. 2018 , 15, 434-442	16
1004	Immunotherapy in treatment naïve advanced non-small cell lung cancer. 2018 , 10, S412-S421	8
1003	Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an mutation. 2018 , 10, 2166-2178	9
1002	Value of combining serum carcinoembryonic antigen and PET/CT in predicting mutation in non-small cell lung cancer. 2018 , 10, 723-731	12
1001	Oncogene-addicted non-small cell lung cancer and immunotherapy. 2018 , 10, S1547-S1555	24
1000	Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. 2018 , 10, 1386-1393	3
999	A case of different mutations in surgically resected synchronous triple lung cancer. 2018 , 10, E255-E259	2
998	Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?. 2018 , 10, S1076-S1080	5
997	Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. 2018 , 7, S13-S18	1
996	Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. 2018 , 10, 2070-2078	8

995	Liquid biopsy guided precision therapy for lung cancers. 2018 , 10, S4173-S4175	2
994	Choosing the Best EGFR TKI in the Era of Precision Medicine. 2018 , 04,	
993	Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial. 2018 , 10, S3071-S3077	0
992	Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants. 2018 , 52, 2110-2118	5
991	Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study. 2018 , 97, e11346	9
990	Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer. 2019 , 17, 944-950	18
989	Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. 2018 , 50, 835-842	41
988	Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin. 2018 , 3, 32	26
987	Receptor Tyrosine Kinase-Targeted Cancer Therapy. 2018 , 19,	103
986	Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. 2018 , 109, 3921-3933	21
985	Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. 2018 , 7,	120
984	Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience. 2018 , 25, e385-e390	3
983	Safety of osimertinib in EGFR-mutated non-small cell lung cancer. 2018 , 17, 1239-1248	17
982	Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors. 2018 , 41, 755-761	16
981	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. 2018 , 119, 1456-1463	19
980	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. 2018 , 18, 1198	13
979	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring mutations: subgroup analysis of the LUX-Lung 6 trial. 2018 , 11, 8575-8587 ¹⁶	
978	Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. 2019 , 12, 537-552	10

977	Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. 2018 , 11, 8201-8209	5
976	Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation. 2018 , 12, 183-190	14
975	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. 2018 , 18, 1231	7
974	Prise en charge thérapeutique des cancers bronchiques non ^petites cellules de stades avancés mutés pour l'EGFR. 2018 , 10, 425-439	0
973	Évaluation, prévention et gestion des toxicités des inhibiteurs de l'ALK et de l'EGFR. 2018 , 10, 454-465	
972	Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. 2018 , 8, 14896	17
971	Combination of Ginsenoside H dripping pills and cyclophosphamide improve paraneoplastic syndrome and inhibit postoperative recurrence via the reversion of Th1/Th2 shift. 2018 , 108, 865-875	5
970	Novel Systemic Treatments for Brain Metastases From Lung Cancer. 2018 , 20, 48	5
969	Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. 2018 , 19, 58	32
968	Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. 2018 , 22, 542-548	8
967	A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. 2018 , 104, 1-8	6
966	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. 2018 , 8, e017240	12
965	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. 2018 , 82, 1031-1038	11
964	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv192-iv237	897
963	Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. 2018 , 10,	2
962	Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs. 2018 , 18, 1033	3
961	Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection. 2018 , 13, e0206386	3
960	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. 2018 , 126, 133-138	21

959	Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. 2018 , 16, 7057-7067	2
958	Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy. 2018 , 506, 266-271	13
957	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. 2018 , 12, 1753466618808659	13
956	A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?. 2018 , 97, e11569	14
955	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. 2018 , 97, e12660	
954	Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. 2018 , 125, 282-290	23
953	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. 2018 , 126, 41-47	21
952	Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. 2018 , 18, 959	12
951	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. 2018 , 14, 2861-2874	75
950	Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect. 2018 , 439, 113-130	6
949	The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. 2018 , 7, S134-S137	3
948	Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in mutant patients with non-small cell lung cancer. 2018 , 9, 2987-2993	1
947	A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. 2018 , 26, 1031-1036	16
946	New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. 2018 , 4,	2
945	Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?. 2018 , 103, 32-40	9
944	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. 2018 , 8, 13379	48
943	Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. 2018 , 124, 241-247	3
942	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. 2018 , 9, 11805-11815	7

941	Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired T790M Mutation. 2018 , 38, 5409-5415	3
940	,,,, and mutation in plasma of small cell lung cancer patients. 2018 , 11, 2217-2226	13
939	Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. 2018 , 6, 203-215	30
938	Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. 2018 , 84, 2877-2888	14
937	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. 2018 , 32, 527-542	9
936	Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype. 2018 , 144, 1413-1422	15
935	Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. 2018 , 36, 1044-1059	
934	Krâpel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer. 2018 , 109, 1775-1786	12
933	Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. 2018 , 4, 1080-1084	69
932	Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program. 2018 , 6, 45-58	1
931	Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report. 2018 , 16, 1046-1050	2
930	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. 2018 , 2018, 8202971	13
929	Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. 2018 , 69, 143-151	16
928	Standardizing biomarker testing for Canadian patients with advanced lung cancer. 2018 , 25, 73-82	16
927	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. 2018 , 123, 60-69	35
926	Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma. 2018 , 2018, 2942618	2
925	Targeting phosphatases of regenerating liver (PRLs) in cancer. 2018 , 190, 128-138	17
924	Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. 2018 , 25, S68-S76	6

923	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. 2018 , 13, 1248-1268	331
922	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. 2018 , 7,	20
921	Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics. 2018 , 16, 1087-1094	5
920	Small Molecules in Oncology. 2018 ,	3
919	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. 2018 , 18, 1021-1030	14
918	A comparison of QuantStudio [®] BD Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. 2018 , 10, 115-121	11
917	Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?. 2018 , 25, S103-S114	32
916	Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. 2018 , 25, S28-S37	17
915	Afatinib. 2018 , 211, 199-215	16
914	Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. 2018 , 38, 4699-4704	4
913	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. 2018 , 124, 293-297	10
912	First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?. 2018 , 8, 94	15
911	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. 2018 , 14, 3-17	17
910	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. 2018 , 7,	41
909	EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. 2018 , 275-293	
908	Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. 2018 , 8, 208	43
907	Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. 2018 , 13, 1383-1392	82
906	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. 2018 , 10,	20

905	A systematic review of targeted agents for non-small cell lung cancer. 2018 , 57, 176-186	34
904	Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in activating mutation-positive advanced non-small-cell lung cancer. 2018 , 25, S9-S17	11
903	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. 2018 , 19, e655-e665	4
902	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. 2018 , 17, 1648-1658	43
901	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. 2018 , 18, 106	8
900	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. 2018 , 8, 530-538	27
899	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. 2018 , 19, 851-864	4
898	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. 2018 , 18, 6	5
897	Treatment of advanced non-small cell lung cancer in the elderly. 2018 , 12, 783-792	4
896	Comparison of detection methods of T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. 2018 , 11, 3335-3343	13
895	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. 2018 , 15, 694-708	151
894	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. 2018 , 35, 819-834	7
893	Efficacy of icotinib in advanced lung squamous cell carcinoma. 2018 , 7, 4456-4466	8
892	Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. 2018 , 11, 529-538	12
891	A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. 2018 , 82, 757-766	2
890	Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. 2018 , 9, 1285-1290	21
889	Afatinib restrains K-RAS-driven lung tumorigenesis. 2018 , 10,	70
888	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. 2018 , 23, 1052-1059	20

887	Targeting EGFR in Lung Cancer: Current Standards and Developments. 2018 , 78, 893-911	40
886	Challenges of dispensing costly tablets with short shelf-life. 2019 , 25, 210-213	1
885	Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. 2019 , 27, 1029-1039	2
884	Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects. 2019 , 10, 4-30	21
883	Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. 2019 , 110, 2884-2893	20
882	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. 2019 , 293, 15-29	23
881	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). 2019 , 20,	55
880	Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. 2019 , 12, 1425-1431	13
879	Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. 2019 , 9, 800	50
878	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. 2019 , 51, 502-509	45
877	Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs. 2019 , 18, 1534735419869491	49
876	Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer. 2019 , 10, 1928-1935	5
875	Treatment of uncommon mutations in non-small cell lung cancer: new evidence and treatment. 2019 , 8, 302-316	45
874	Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. 2019 , 8, 286-301	39
873	Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. 2019 , 12, 831-840	2
872	Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. 2019 , 11, 2350-2360	19
871	Systematic review and network meta-analysis of first-line therapy for advanced -positive non-small-cell lung cancer. 2019 , 15, 2857-2871	16
870	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. 2019 , 15, 2139-2149	1

869	A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. 2019 , 137, 7-13	19
868	Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. 2019 , 94, 1623-1640	481
867	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. 2019 , 8,	18
866	Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer. 2019 , 15, 2795-2805	14
865	The Extract of Inhibited the Proliferation of Cisplatin-Resistant A549 Lung Cancer Cells by Downregulation of H-Ras. 2019 , 22, 823-832	1
864	Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. 2019 , 19, 701	5
863	Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. 2019 , 11, 301-308	8
862	Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. 2019 , 9, 1689-1704	2
861	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. 2019 , 10, 3717-3727	20
860	Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis. 2019 , 23, 657-665	0
859	Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. 2019 , 12, 5467-5484	22
858	Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer. 2019 , 68, 751-760	18
857	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). 2019 , 105, 3-14	6
856	Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. 2019 , 30, 1004-1012	4
855	EGFR Targeted Therapy. 2019 , 1-30	0
854	First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. 2019 , 30, 1852-1855	7
853	Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study. 2019 , 11, 7953-7965	12
852	Microfluidic Technologies for cfDNA Isolation and Analysis. 2019 , 10,	12

851	Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. 2019 , 367, l5460	52
850	Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. 2019 , 11, 8539-8546	16
849	The Mechanisms Underlying the Cytotoxic Effects of Copper Via Differentiated Embryonic Chondrocyte Gene 1. 2019 , 20,	8
848	Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?. 2019 , 11, S1837-S1840	1
847	Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. 2019 , 19, 1006	9
846	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. 2019 , 6, 233	8
845	Selecting short length nucleic acids localized in exosomes improves plasma mutation detection in NSCLC patients. 2019 , 19, 251	14
844	Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases. 2019 , 10, 2106-2116	6
843	Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma. 2019 , 10, 2267-2273	7
842	Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer. 2019 , 18, 2677-2683	5
841	Optimizing outcomes and treatment sequences in mutation-positive non-small-cell lung cancer: recent updates. 2019 , 15, 2983-2997	18
840	Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. 2019 , 9, 715	8
839	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. 2019 , 119, 77-86	12
838	Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. 2019 , 14, e0221575	7
837	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. 2019 , 11,	12
836	Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. 2019 , 12, 6535-6548	15
835	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. 2019 , 84, 1065-1071	1
834	Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. 2019 , 19, 896	21

833	Molecular mechanisms of Cisplatin- induced placental toxicity and teratogenicity in rats and the ameliorating role of N-acetyl-cysteine. 2019 , 115, 105579	2
832	Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data. 2019 , 16, 341-349	2
831	Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer. 2019 , 18, 3887-3895	12
830	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. 2019 , 46, 271-283	43
829	Osimertinib in first line setting: for Asian patients. 2019 , 8, 550-552	
828	Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. 2019 , 12, 7399-7404	7
827	Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. 2019 , 30, 1978-1984	40
826	New Horizons in -Mutant Lung Cancer: Dawn After Darkness. 2019 , 9, 953	55
825	Human Protein Complex Signatures for Drug Repositioning. 2019 ,	2
824	First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis. 2019 , 14, e0223530	4
823	Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). 2019 , 137, 113-122	73
822	Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer. 2019 , 12, 8151-8159	7
821	Electrochemically controllable actuation of liquid metal droplets based on Marangoni effect. 2019 , 126, 084505	5
820	Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. 2019 , 25, 6967-6975	25
819	Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib. 2019 , 58, 101-104	2
818	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer. 2019 , 25, 2575-2587	33
817	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. 2019 , 15, 805-816	18
816	Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. 2019 , 134, 1-6	9

815	A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. 2019 , 38, 211	9
814	A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the third-generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. 2019 , 125, 370-381	6
813	Targeted Therapies in Non-small-Cell Lung Cancer. 2019 , 178, 3-43	11
812	Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. 2019 , 38, 266	36
811	Cas clinique n° 5 : Adaptation thérapeutique chez un patient atteint de cancer du poumon EGFR-mut. 2019 , 11, 34-37	
810	Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives. 2019 , 459, 240-247	9
809	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. 2019 , 37, 2235-2245	94
808	Comparative Analysis of Two Methods for the Detection of Mutations in Plasma Circulating Tumor DNA from Lung Adenocarcinoma Patients. 2019 , 11,	5
807	Comparing the efficacy of targeted next-generation sequencing in the identification of somatic mutations in circulating tumor DNA from different stages of lung cancer. 2019 , 66, 652-660	5
806	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. 2019 , 20, 49	5
805	Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. 2019 , 79, 823-831	11
804	Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. 2019 , 20, e576-e583	15
803	Cost-of-illness study for non-small-cell lung cancer using real-world data. 2019 , 26, 102-107	18
802	Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. 2019 , 10, 1461-1468	7
801	Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. 2019 , 36, 57	11
800	ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment. 2019 , 27, 100837	6
799	Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. 2019 , 19, 369	8
798	Cascade-amplification of therapeutic efficacy: An emerging opportunity in cancer treatment. 2019 , 11, e1555	4

797	AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. 2019 , 10, 1812	57
796	Osimertinib for -mutant non-small cell lung cancer: place in therapy and future perspectives. 2019 , 11, S249-S252	1
795	Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. 2019 , 10, 1078-1085	3
794	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. 2019 , 24, 731-770	63
793	Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors. 2019 , 14, e0215923	2
792	Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. 2019 , 11,	20
791	The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations. 2019 , 10, 610-614	3
790	EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 1-11	3
789	Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis. 2019 , 11, 2677-2690	6
788	Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer. 2019 , 32, 360-366	4
787	First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. 2019 , 11, 1758835919836374	20
786	Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure. 2019 , 10, 957-965	13
785	Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. 2019 , 25, 4881-4887	5
784	Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study. 2019 , 125, e487-e496	3
783	Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis. 2019 , 15, 1481-1491	9
782	Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. 2019 , 15, 1493-1504	5
781	Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. 2019 , 115-131	
780	Pulsed-dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split-faced controlled trial. 2019 , 51, 584-591	

779	Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study. 2019 , 18, 1534735419827079	8
778	Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). 2019 , 49, 554-558	11
777	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. 2019 , 10, 880-889	8
776	Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. 2019 , 20,	36
775	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. 2019 , 19, 547-559	11
774	A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). 2019 , 135, 175-180	13
773	Targeting exon 20 insertion mutations in non-small cell lung cancer. 2019 , 4, 5	129
772	Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study. 2019 , 2019, 9136249	3
771	Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. 2019 , 26, e81-e93	20
770	The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. 2019 , 10, 885-892	2
769	Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. 2019 , 12, 1521-1538	3
768	First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. 2019 , 12, 1413-1421	30
767	Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. 2019 , 24, 917-926	13
766	Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 625-635	21.7 264
765	Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. 2019 , 144, 79-89	38
764	First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. 2019 , 133, 10-19	14
763	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. 2019 , 132, 126-131	17
762	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. 2019 , 24, 1270-1284	14

761	Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations. 2019 , 14, e0215292	4
760	Clinical development of targeted and immune based anti-cancer therapies. 2019 , 38, 156	93
759	Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. 2019 , 49, 671-675	9
758	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. 2019 , 7, 387-401	398
757	Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib. 2019 , 14, e70-e72	3
756	Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. 2019 , 19, 68	6
755	A Comparative Study of Genetic Profiles of Key Oncogenesis-Related Genes between Primary Lesions and Matched Lymph Nodes Metastasis in Lung Cancer. 2019 , 10, 1642-1650	5
754	Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer. 2019 , 10, 686-694	2
753	Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. 2019 , 17, 52	16
752	Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. 2019 , 10, 839-847	16
751	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. 2019 , 21, 21	54
750	A polysaccharide from <i>Hedyotis diffusa</i> interrupts metastatic potential of lung adenocarcinoma A549 cells by inhibiting EMT via EGFR/Akt/ERK signaling pathways. 2019 , 129, 706-714	11
749	Drug-Induced Diarrhea. 2019 , 208-224	
748	Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. 2019 , 130, 149-155	25
747	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. 2019 , 145, 1569-1579	24
746	Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs. 2019 , 215, 946-951	2
745	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. 2019 , 8, 1134-1151	2
744	Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints. 2019 , 8, S334-S338	1

743	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. 2019 , 8, 989-999	16
742	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. 2019 , 4, e000532	5
741	Current Approaches in NSCLC Targeting K-RAS and EGFR. 2019 , 20,	23
740	Poor Prognosis With Coexistence Of T790M Mutation And Common -Activating Mutation In Non-Small Cell Lung Cancer. 2019 , 11, 9621-9630	3
739	Full Issue PDF. 2019 , 1, I-CXCII	
738	Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). 2019 , 1, 172-178	20
737	Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. 2019 , 20, 270	16
736	Afatinib, an irreversible ErbB family blocker for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer. 2019 , 2, e18	1
735	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. 2019 , 8, S265-S279	10
734	Report from the ESMO 2019 Congress, Barcelona, September 27th âOctober 1st 2019. 2019 , 12, 65-82	
733	Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report. 2019 , 98, e13924	1
732	A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. 2019 , 27, e51	3
731	Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study. 2019 , 8, LMT15	2
730	Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. 2019 , 8, S247-S264	27
729	Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. 2019 , 11, 10239-10248	7
728	Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. 2019 , 9, 18202	12
727	Highly sensitive and specific screening of EGFR mutation using a PNA microarray-based fluorometric assay based on rolling circle amplification and graphene oxide.. 2019 , 9, 38298-38308	6
726	Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study. 2019 , 24, 157-e64	37

725	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. 2019 , 26, 96-101	13
724	Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases. 2019 , 20, e247-e250	16
723	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. 2019 , 49, 29-36	56
722	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. 2019 , 30, 171-210	121
721	Liquid Biopsy and Lung Cancer. 2019 , 63, 489-496	39
720	Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. 2019 , 15, 637-652	45
719	EGFR Mutations. 2019 , 477-486	2
718	The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma. 2019 , 20, e195-e207	7
717	Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemo-naïve Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. 2019 , 20, 134-138	15
716	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. 2019 , 127, 37-43	35
715	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. 2019 , 19, 55	17
714	Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. 2019 , 14, e0209709	22
713	First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naïve Mutation-Positive Non-Small Cell Lung Cancer?. 2019 , 20,	74
712	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. 2019 , 75, 697-706	2
711	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. 2019 , 14, 99-106	44
710	Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). 2019 , 127, 103-111	42
709	Clinicopathologic characteristics and outcome of patients with different EGFR mutations. 2019 , 15, 166-171	6
708	Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?. 2019 , 31, 1-7	14

707	Synthesis and biological evaluation of cyanoaziridine phosphine oxides and phosphonates with antiproliferative activity. 2019 , 163, 736-746	13
706	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. 2019 , 20, e186-e194	27
705	Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. 2019 , 127, 12-18	28
704	Resistance to molecularly targeted therapy in non-small-cell lung cancer. 2019 , 57, 20-26	32
703	Absolute Bioavailability of Osimertinib in Healthy Adults. 2019 , 8, 198-207	16
702	Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. 2020 , 26, 13-22	7
701	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. 2020 , 21, 153-164	15
700	A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. 2020 , 15, 91-100	17
699	Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA. 2020 , 98, 23-28	5
698	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. 2020 , 32, e1-e9	1
697	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. 2020 , 21, 1-14.e3	10
696	Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. 2020 , 15, 26-41	18
695	Cancer of the Lung: Non-small Cell Lung Cancer and Small Cell Lung Cancer. 2020 , 1108-1158.e16	5
694	Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study. 2020 , 146, 2510-2517	8
693	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. 2020 , 9, 4430-4445	
692	Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs. 2020 , 146, 407-416	3
691	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. 2020 , 38, 115-123	155
690	Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. 2020 , 573, 118785	11

689	Therapies after first-line afatinib in patients with m NSCLC in Japan: retrospective analysis of LUX-Lung 3. 2020 , 16, 49-60	2
688	Tumor-educated platelet as liquid biopsy in lung cancer patients. 2020 , 146, 102863	14
687	Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors. 2020 , 8, 332-342	15
686	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. 2020 , 146, 102858	28
685	Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan. 2020 , 147, 1107-1116	8
684	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. 2020 , 141, 37-43	10
683	Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations. 2020 , 21, e216-e228	45
682	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. 2020 , 125, 49-57	23
681	Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations. 2020 , 14, 125-136	30
680	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). 2020 , 38, 488-495	121
679	Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. 2020 , 140, 19-26	5
678	Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report. 2020 , 11, 447-450	5
677	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. 2020 , 39, 1846-1859	15
676	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. 2020 , 21, e191-e204	14
675	mPR ¹ mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway. 2020 , 59, 179-192	7
674	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). 2020 , 38, 793-803	12
673	Performance of F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer. 2020 , 10, 568857	8
672	Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. 2020 , 12, 4057-4069	2

671	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. 2020 , 149, 33-40	2
670	Afatinib for the first-line treatment of mutation-positive NSCLC in China: a review of clinical data. 2020 , 16, 2569-2586	0
669	Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry. 2020 , 11, 3346-3356	1
668	Overview of current targeted therapy in gallbladder cancer. 2020 , 5, 230	24
667	Chemotherapy should be performed in epidermal growth factor receptor mutation-positive lung adenocarcinoma patients who had progressive disease to the first epidermal growth factor receptor-tyrosine kinase inhibitor. 2020 , 31, 959-965	
666	Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. 2021 , 27, 1665-1673	
665	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon Mutations: Are They Different From Those with Common Mutations?. 2020 , 9,	3
664	Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation-Positive Lung Cancer Cells. 2020 , 12,	7
663	Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. 2020 , 29, 1389-1406	1
662	Traitement des cancers bronchiques non ^ petites cellules de stades avancs muts EGFR : quels inhibiteurs ? Quelles squences thfapeutiques ?. 2020 , 12, 2S195-2S211	1
661	Value of interim F-FDG PET/CT for predicting progression-free survival in stage IIIB/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy. 2020 , 149, 137-143	2
660	F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. 2020 , 9, 563-574	8
659	Tyrosine Kinase Receptors in Oncology. 2020 , 21,	12
658	Effect of BBlocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs. 2020 , 10, 583529	6
657	Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. 2020 , 9, 1952-1962	6
656	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. 2020 , 10, 588862	4
655	Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. 2020 , 5, e001011	8
654	High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR. 2020 , 475, 15-25	7

653	Making the case for EGFR TKI sequencing in mutation-positive NSCLC: a GioTag study US patient analysis. 2020 , 16, 1585-1595	3
652	Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer. 2020 , 492, 31-43	2
651	Repurposing of Kinase Inhibitors for Treatment of COVID-19. 2020 , 37, 167	61
650	Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. 2020 , 9, 2062-2071	6
649	mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. 2020 , 12, 3836-3843	29
648	Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment. 2020 , 12,	5
647	Human genetic diversity in health and disease. 2020 , 123-136	1
646	Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer. 2020 , 16, 1957-1967	1
645	Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. 2020 , 111, 3705-3713	5
644	First-line treatment selection with organoids of an m + m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. 2020 , 12, 3764-3773	0
643	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. 2020 , 11, 73-103	3
642	Management of brain metastases according to molecular subtypes. 2020 , 16, 557-574	44
641	Targeted Therapies in Early Stage NSCLC: Hype or Hope?. 2020 , 21,	20
640	Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. 2020 , 77, 1466-1476	3
639	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. 2020 , 15, 1857-1870	7
638	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. 2020 , 86, 517-525	2
637	Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With Mutations. 2020 , 10, 1455	6
636	The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. 2020 , 10, 14965	9

635	Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2020 , 22, 119	5
634	Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. 2020 , 20, 240	6
633	Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study. 2020 , 48, 300060520937093	
632	Genomic Strategies for Personalized Cancer Therapy. 2020 , 1-60	
631	Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination. 2020 , 80, 4426-4438	12
630	erbB in NSCLC as a molecular target: current evidences and future directions. 2020 , 5,	12
629	Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. 2020 , 13, 12539-12547	0
628	Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?. 2020 , 9, 951-955	1
627	Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations. 2020 , 43, 686-693	3
626	A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations. 2020 , 99, e23455	0
625	The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. 2020 , 13,	8
624	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. 2021 , 107, 376-384	0
623	Switching from first or second generation EGFR-TKI to osimertinib in mutation-positive NSCLC. 2020 , 9, LMT29	1
622	A validated ultra-performance LC-MS/MS method for quantifying a novel oral EGFR inhibitor FCN-411 in human plasma. 2020 , 12, 295-304	
621	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. 2020 , 38, 1854-1861	6
620	LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer. 2020 , 10, 656	9
619	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. 2020 , 12,	27
618	QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer. 2020 , 44, 100594	1

617	Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway. 2020 , 159, 104934	10
616	Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives. 2020 , 20, 531-542	2
615	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. 2020 , 9,	3
614	Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment. 2020 , 31, 310-313	1
613	Canadian consensus: a new systemic treatment algorithm for advanced mutated non-small-cell lung cancer. 2020 , 27, e146-e155	7
612	Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism. 2020 , 10, 337-345	3
611	Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study. 2020 , 12, 3293-3299	3
610	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment. 2020 , 11, 2188-2195	8
609	Targeted Therapy for Non-Small Cell Lung Cancer. 2020 , 41, 409-434	6
608	Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. 2020 , 12,	9
607	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. 2020 , 9,	9
606	Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601). 2020 , 25, e1451-e1456	3
605	Afatinib for the treatment of mutation-positive NSCLC: A review of clinical findings. 2020 , 26, 1461-1474	13
604	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. 2020 , 12, 2859-2876	6
603	A novel histone acetyltransferase inhibitor A485 improves sensitivity of non-small-cell lung carcinoma cells to TRAIL. 2020 , 175, 113914	10
602	Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. 2020 , 31, 517-524	14
601	Successful treatment of advanced lung adenocarcinoma complicated with Lambert-Eaton myasthenic syndrome: A case report and literature review. 2020 , 11, 1334-1338	1
600	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. 2020 , 26, 3162-3171	8

599	Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon Mutations. 2020 , 10, 224	10
598	Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. 2020 , 14, 565-576	5
597	Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments. 2020 , 10, e032336	5
596	Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. 2020 , 11, 935-942	9
595	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic review. 2020 , 153, 103035	2
594	Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments. 2020 , 146, 2329-2338	12
593	Icotinib as Adjuvant Treatment for Stage II-IIIa Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial. 2020 , 12, 4633-4643	4
592	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). 2020 , 21, e592-e596	3
591	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. 2020 , 20, 103	8
590	Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. 2020 , 107, 62-71	15
589	Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. 2020 , 141, 107-113	13
588	Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer.. 2020 , 9, 372-381	1
587	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. 2020 , 28, 861-872	6
586	Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. 2020 , 40, 43-59	22
585	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. 2020 , 15, 803-815	77
584	Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. 2020 , 42, 338-350.e4	8
583	Precision Management of Advanced Non-Small Cell Lung Cancer. 2020 , 71, 117-136	52
582	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. 2020 , 99, e18726	16

581	Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. 2020 , 21, 428-436.e2	7
580	Epidermal Growth Factor Receptor Mutations. 2020 , 30, 127-136	8
579	Multi-stimuli responsive polymeric prodrug micelles for combined chemotherapy and photodynamic therapy. 2020 , 8, 5267-5279	22
578	Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. 2020 , 1873, 188363	6
577	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. 2020 , 143, 67-72	8
576	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. 2020 , 19, 589-599	5
575	Biopsy on progression in patients with mutation-positive advanced non-small-cell lung cancer-a Canadian experience. 2020 , 27, 27-33	2
574	Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. 2020 , 21, 931-943	1
573	Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. 2020 , 111, 1724-1738	8
572	Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan. 2020 , 21, 211-221	0
571	Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. 2020 , 7, 3-15	2
570	EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy. 2020 , 20, 365-372	4
569	Impact of pulmonary interstitial lesions on efficacy and prognosis of EGFR-TKI-treated advanced non-small cell lung cancers. 2020 , 12, 839-848	
568	HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. 2021 , 42, 115-119	5
567	Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy. 2021 , 11, 927-943	11
566	Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. 2021 , 39, 232-236	2
565	Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas. 2021 , 111, 290-295	1
564	Development, internal validation and calibration of a risk score to predict survival in patients with -mutant non-small cell lung cancer. 2021 , 74, 116-122	3

563	The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis. 2021 , 46, 256-266	4
562	Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis. 2021 , 46, 310-318	2
561	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). 2021 , 22, 147-151	2
560	Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. 2021 , 22, e70-e83	3
559	Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. 2021 , 17, 103-115	0
558	AZD9291 Resistance Reversal Activity of a pH-Sensitive Nanocarrier Dual-Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC. 2021 , 8, 2002922	10
557	Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. 2021 , 12, 444-452	1
556	Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound-guided transbronchial needle aspiration samples for next-generation sequencing analysis. 2021 , 12, 251-258	5
555	Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. 2021 , 12, 329-338	1
554	Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis. 2021 , 236, 4538-4554	6
553	Benefits and limitations of real-world evidence: lessons from mutation-positive non-small-cell lung cancer. 2021 , 17, 965-977	10
552	2020 Innovation-Based Optimism for Lung Cancer Outcomes. 2021 , 26, e454-e472	4
551	Predicting potential residues associated with lung cancer using deep neural network. 2021 , 822, 111737	0
550	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. 2021 , 16, 764-773	47
549	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. 2021 , 26, 281-287	6
548	Outcomes of gefitinib therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients with active EGFR mutations receiving stereotactic body radiotherapy: a single-institute retrospective study. 2021 , 4, 72	
547	New Approved First-line Combining Therapy of NSCLC in 2020. 2021 , 245, 03057	
546	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. 2021 , 67, 534-542	2

545	The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. 2021 , 13, 17588359211018022	0
544	First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. 2021 , 13, 17588359211035710	3
543	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With Mutations. 2021 , 2, 100107	6
542	Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in -Mutant Non-Small Cell Lung Cancer Cells. 2021 , 13,	2
541	Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. 2021 , 24, 328-338	
540	Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis. 2021 , 28, 100407	1
539	Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. 2021 , 147, 2145-2152	0
538	Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene ()-mutations in first-line for advanced non-small cell lung cancer.. 2021 , 4, 740-744	
537	Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy. 2021 , 20, 15347354211037917	
536	Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer. 2021 , 42, 648-654	1
535	Almonertinib-induced interstitial lung disease: A case report. 2021 , 100, e24393	5
534	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. 2021 , 28, 100416	
533	Management of Brain Metastases. 2021 , 115-137	
532	Afatinib as first-line treatment in patients with -mutated non-small cell lung cancer in routine clinical practice. 2021 , 13, 17588359211012361	2
531	Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. 2021 , 21, 52	3
530	Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells. 2021 , 21, 532-541	7
529	Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation. 2021 , 12, 1067-1073	2
528	Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. 2021 , 100, e24640	2

527	Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. 2021 , 9, 1329-1335	2
526	A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors.. 2021 , 10, 1119-1130	0
525	Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma. 2021 , 12, 989-992	1
524	Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. 2021 , 10, 193-206	0
523	Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. 2021 , 16, 165-176	18
522	Biomarcadores moleculares y celulares. Implicaciones en la terapia dirigida. 2021 , 13, 1418-1423	
521	Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report. 2021 , 100, e24380	0
520	Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. 2021 , 13,	2
519	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. 2021 , 100, e23712	1
518	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. 2021 , 13,	23
517	Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. 2021 , 39, 697-700	1
516	High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. 2021 , 13, 1476-1484	1
515	EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis. 2021 , 16, e0247860	0
514	Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. 2021 , 11, 639947	6
513	Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. 2021 , 39, 537-548	2
512	Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation. 2021 , 121, 170-170	3
511	Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer. 2021 , 11, 620154	
510	Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. 2021 , 38, 2038-2053	6

509	Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. 2021 , 8, 141-152	1
508	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. 2021 , 10,	13
507	A phase II study of first-line afatinib for patients aged ≥5 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. 2021 , 21, 208	3
506	Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis. 2021 , 10, 325-335	1
505	Proteomics in aging research: A roadmap to clinical, translational research. 2021 , 20, e13325	10
504	Potential Impacts of Promoter Polymorphisms on the Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan. 2021 , 12,	1
503	Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma.. 2021 , 10, 1549-1558	
502	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. 2021 , 3, CD010383	6
501	Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. 2021 , 6, 161-171	0
500	Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. 2021 , 41, 483-488	
499	Overcoming therapy resistance in EGFR-mutant lung cancer.. 2021 , 2, 377-391	23
498	Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review. 2021 , 19, 88	3
497	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. 2021 , 160, 103299	3
496	Lung Adenocarcinoma Patient Harboring -KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review. 2021 , 11, 605853	0
495	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. 2021 , 160, 103305	2
494	Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center. 2021 , 27, e930738	1
493	Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients. 2021 , 31, 281-294	4
492	Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling. 2021 , 22,	5

491	Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively. 2021 , 21, 445	0
490	Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. 2021 , 12, 1598-1604	1
489	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. 2021 , 160, 103300	1
488	Updates in Pharmacogenetics of Non-Small Cell Lung Cancer.	1
487	Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report.. 2021 , 10, 1941-1946	1
486	Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review. 2021 , 10, 2237-2251	1
485	Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer. 2021 , 13, 3230-3234	1
484	VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma. 2021 , 35, 297-302	
483	Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. 2021 , 11, 684073	2
482	The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. 2021 , 11, 9629	1
481	Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer. 2021 , 11, 602924	2
480	Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. 2021 , 155, 20-27	10
479	Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA. 2021 , 15, 2423-2438	5
478	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. 2021 , 10,	4
477	Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. 2021 , 112, 2371-2380	5
476	Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer. 2021 , 12, 1824-1830	2
475	First-Line Afatinib plus Cetuximab for -Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. 2021 , 27, 4168-4176	1
474	Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis. 2021 , 16, 193-201	2

473	Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. 2021 , 19, 145	6
472	Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. 2021 , 21, 495	3
471	Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. 2021 , 22, 1581-1590	0
470	Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review. 2021 , 9, 950	2
469	Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study. 2021 , 16, e0253335	1
468	Investigation of in vitro activities of Cu ₂ ZnSnS ₄ nanoparticles in human non-small cell lung cancer. 2021 , 27, 102304	0
467	A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. 2021 , 6, 100115	11
466	NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. 2021 , 10,	7
465	Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis. 2021 ,	1
464	A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study. 2021 , 10781552211020798	0
463	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. 2021 , 13,	9
462	A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The EGFR-PRO Study. 2021 , 12,	1
461	Relationship between epidermal growth factor receptor mutations and CT features in patients with lung adenocarcinoma. 2021 , 76, 473.e17-473.e24	1
460	EGFR tyrosine kinase inhibitors for mutation-positive non-small-cell lung cancer: outcomes in Asian populations. 2021 , 17, 2395-2408	5
459	Stabilized Peptide Covalent Inhibitors. 2021 , 159-180	
458	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. 2021 , 2, 173-196	10
457	Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events. 2021 , 2021, 2414897	
456	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. 2021 , 8, 570921	0

455	Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. 2021 , 14,	7
454	Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. 2021 , 51, 1269-1276	2
453	Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with Mutations. 2021 , 10,	2
452	An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. 2021 , 21, 802	1
451	High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. 2021 , 13,	1
450	A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. 2021 , 11, 692703	0
449	Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage III non-small cell lung cancer (NSCLC) patients with baseline tissue mutations. 2021 , 10, 3213-3225	3
448	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. 2021 ,	5
447	Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. 2021 , 30,	1
446	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. 2021 , 11, 709877	1
445	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. 2021 , 17, 2513-2527	0
444	Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. 2021 , 21, 859	2
443	Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. 2021 , 12, 720687	0
442	Clinicopathological features of patients with transformation from mutant lung adenocarcinoma to small cell lung cancer.. 2021 , 10, 3694-3704	2
441	Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. 2021 , 14, 4579-4597	4
440	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. 2021 , 12, 93-102	0
439	How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutated NSCLC treatment (Review). 2021 , 22, 1150	1
438	Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2021 , 8, 715318	1

437	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. 2021 , 5,	3
436	Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. 2021 , 39, 1429-1442	0
435	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. 2021 , 16, 2029-2039	3
434	EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma. 2021 , 11, 691915	2
433	Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with exon 19 deletions or exon 21 mutations. 2021 , 17, 2867-2881	0
432	Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC. 2021 , 46, 100787	2
431	The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon Mutations-The Mutation Patterns, Use of Different Generations of -TKIs, and Concurrent Genetic Alterations. 2021 , 11, 646577	3
430	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. 2021 , 14, 987-996	1
429	The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis. 2021 , 100, e27038	1
428	Mathematical model of STAT signalling pathways in cancer development and optimal control approaches. 2021 , 8, 210594	2
427	Structure-based classification predicts drug response in EGFR-mutant NSCLC. 2021 , 597, 732-737	30
426	Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. 2021 , 12, 2655-2665	2
425	Updates in the molecular pathology of non-small cell lung cancer. 2021 , 38, 54-61	3
424	Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. 2021 , 9, 69	1
423	Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. 2021 , 57,	0
422	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. 2021 , 21, 1165-1178	2
421	Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. 2021 , 13,	1
420	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. 2021 , 2, 100206	1

419	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. 2021 , 9,	2
418	Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. 2021 , 150, 626	1
417	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. 2021 ,	3
416	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). 2021 , 162, 9-15	2
415	EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. 2021 , 120, 1729-1739	1
414	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. 2021 , 41, 4215-4228	4
413	TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. 2021 , 14, 101163	2
412	Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. 2021 , 10, 3823-3839	3
411	GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib. 2021 ,	
410	Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. 2021 , 13,	3
409	Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. 2021 , 166, 103454	5
408	The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. 2021 , 160, 118-126	2
407	Nuclear Pore Glycoprotein 62 Genetic Variant rs9523 is Associated with Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients. 2021 , 14, 1291-1302	
406	Molecular Targetable Pathways âEGFR. 2022 , 844-852	
405	Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.. 2021 , 10, 184-194	
404	Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1. 2021 , 12, 387-396	7
403	Breakthrough in targeted therapy for non-small cell lung cancer. 2021 , 133, 111079	21
402	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. 2021 , 22,	7

401	A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). 2021 , 10, 252-260	2
400	Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring mutations. 2021 , 10, 183-192	1
399	Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. 2021 , 12, 643-649	2
398	Introduction. 2015 , 1-3	1
397	Stratifying Cancer Therapies by Molecular Interactions and Imaging. 2017 , 315-358	1
396	Neue Arzneimittel 2013. 2014 , 47-145	2
395	Genome-wide identification and characterization of long non-coding RNAs involved in acquired resistance to gefitinib in non-small-cell lung cancer. 2020 , 87, 107288	1
394	First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. 2021 , 12, 287-296	1
393	B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns. 2020 , 2020, 8824805	3
392	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. 2021 , 27, 1463-1475	26
391	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. 2020 , 12, 1758835919895756	21
390	TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy. 2020 , 26, e922703	3
389	Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer. 2015 , 10, e0128970	7
388	Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. 2015 , 10, e0140794	19
387	Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. 2016 , 11, e0156728	52
386	Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells. 2016 , 11, e0158395	16
385	Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. 2017 , 12, e0171137	40
384	The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. 2017 , 12, e0177822	4

383	The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. 2018 , 13, e0192161	18
382	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. 2018 , 111, 484-488	4
381	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study). 2019 , 24, e318-e326	3
380	Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. 2020 , 12, 7129-7162	3
379	Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. 2020 , 12, 14244-14270	10
378	Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. 2017 , 8, 559-565	6
377	Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer. 2016 , 7, 59049-59057	12
376	Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. 2016 , 7, 68442-68448	7
375	Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. 2017 , 8, 9134-9143	6
374	Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. 2017 , 8, 1343-1353	27
373	Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats. 2017 , 8, 26648-26661	8
372	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. 2017 , 8, 32626-32638	14
371	Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. 2017 , 8, 55760-55765	0
370	Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis. 2017 , 8, 57356-57364	11
369	Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients. 2017 , 8, 63846-63856	19
368	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. 2017 , 8, 77897-77914	15
367	PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. 2017 , 8, 101535-101544	29
366	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). 2018 , 9, 8253-8262	15

365	Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. 2018 , 9, 21512-21529	7
364	Prognostic factors of afatinib as a first-line therapy for advanced mutation-positive lung adenocarcinoma: a real-world, large cohort study. 2018 , 9, 23749-23760	14
363	Targeted therapies for advanced non-small cell lung cancer. 2018 , 9, 37589-37607	36
362	Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. 2015 , 6, 2164-79	35
361	Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. 2015 , 6, 20466-73	22
360	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. 2015 , 6, 33602-11	37
359	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. 2015 , 6, 34030-7	13
358	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. 2015 , 6, 38789-803	104
357	Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. 2016 , 7, 3635-44	16
356	SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. 2016 , 7, 638-55	25
355	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. 2016 , 7, 12404-13	165
354	Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis. 2016 , 7, 20093-108	26
353	Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?. 2016 , 4, 225	5
352	The aftermath of LUX-Lung 7 study-what have we learnt from it?. 2016 , 4, 294	1
351	Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial). 2016 , 4, 313	2
350	Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. 2017 , 5, 371	2
349	Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). 2018 , 6, 140	12
348	Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. 2017 , 5, 481	6

347	Osimertinib in first-line treatment-is a comparison not proof?. 2018 , 6, 57	3
346	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. 2018 , 6, 143	6
345	Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key. 2019 , 7, S48	2
344	EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.. 2019 , 8, S23-S47	19
343	Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.. 2019 , 8, 2151-2163	4
342	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. 2020 , 9, 2656-2673	5
341	Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. 2016 , 28, 339-47	9
340	Uncommon mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. 2017 , 29, 543-552	15
339	Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study. 2019 , 31, 339-348	4
338	Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. 2020 , 13, 9305-9321	10
337	Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer. 2020 , 13, 10621-10630	3
336	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. 2020 , 27, 5274-5316	9
335	Progress in Research on Tumor Metastasis Inhibitors. 2020 , 27, 5758-5772	1
334	Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer. 2018 , 21, 711-717	3
333	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. 2019 , 19, 595-630	17
332	Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. 2019 , 14, 120-128	8
331	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. 2018 , 18, 1235-1240	5
330	A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer. 2018 , 19, 1761-1766	4

329	Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). 2020 , 13,	7
328	Non-small cell lung cancer. 2017 , 63, 861-874	6
327	[Detection and Analysis of EGFR and KRAS Mutations ?in the Patients with Lung Squamous Cell Carcinomas]. 2015 , 18, 621-5	2
326	[China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)]. 2016 , 19, 1-15	8
325	[EGFR-TKI ADR Management Chinese Expert Consensus]. 2019 , 22, 57-81	4
324	Anti-Cancer Therapy of Advanced Lung Cancer in Elderly Patients. 2014 , 87, 537	1
323	Targeted Therapy for Non-Small Cell Lung Cancer. 2020 , 95, 78-88	1
322	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. 2015 , 4, 36-54	389
321	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. 2014 , 3, 370-2	32
320	Clinical trials for lung cancer in China. 2014 , 3, 311-6	2
319	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. 2015 , 4, 67-81	186
318	Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?. 2015 , 4, 223-7	15
317	Treatment of advanced squamous cell carcinoma of the lung: a review. 2015 , 4, 524-32	51
316	The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). 2015 , 3, 96	16
315	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. 2019 , 2, 36	2
314	Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. 2017 , 54, 89-103	3
313	T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. 2020 , 37, 13-18	2
312	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. 2019 , 8, 1-17	6

311	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. 2017 , 49, 1001-1011	29
310	Carcinomatous meningitis and EGFR mutation. 2015 , 23, 14-18	2
309	UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. 2018 , 51, 642-647	15
308	High feasibility of liquid-based cytological samples for detection of EGFR mutations in Chinese patients with NSCLC. 2014 , 15, 7885-9	15
307	Quantitative Review of Oral Cancer Research Output from Pakistan. 2015 , 16, 4733-9	6
306	Using implementation science to advance cancer prevention in India. 2015 , 16, 3639-44	10
305	Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. 2020 , 12, e12128	2
304	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based p.T790M in non-small-cell lung cancer patients. 2021 , 10, 3888-3901	3
303	Lung Cancer. 2021 , 481-515	
302	Algorithme thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de lâEGFR. 2021 , 13, 2S135-2S154	
301	Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. 2021 , 12, 912-925	0
300	Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis. 2021 , 2021, 3621828	2
299	Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. 2021 , 10, 8595-8603	1
298	Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. 2021 , 9,	0
297	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. 2022 , 49, 61-81	1
296	Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. 2021 , 10,	0
295	Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer. 2021 , 19, 339	5
294	Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. 2021 ,	6

293	Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned. 2021 , 10,	0
292	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. 2021 , 1-10	2
291	Distinct and common features of numerical and structural chromosomal instability across different cancer types.	
290	Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. 2021 , 12, 698447	1
289	Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study. 2021 , 12, 3263-3272	1
288	QT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study. 2021 , 8, 684661	1
287	Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies. 2021 , 6, 100280	4
286	Development of New Drugs for Non-small Cell Lung Cancer. 2014 , 54, 898-902	
285	EGFR-Targeted Therapies in Non-small Cell Lung Cancer. 2014 , 31-66	
284	Pitfalls in Clinical Research. The Case of the New Antineoplastic Agents. 2014 , 1, GRHTA.5000183	
283	Strategy on Patients with EGFR Mutation. 2015 , 133-145	
282	Advances in Radiotherapy for Locally Advanced NSCLC. 2015 , 69-94	
281	Development and Current Situation of Treatment for Patients with Acquired Resistance to EGFR-TKIs. 2015 , 55, 932-935	
280	Clinical Benefits Associated with First Line Treatment Using Afatinib. 2015 , 55, 866-870	
279	Therapy options for advanced NSCLC. 2015 , 5-25	
278	Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer. 2016 , 90, 1-6	1
277	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. 2016 , 179-188	
276	Current status and prospects of targeted therapies non-small cell lung cancer. 2016 , 10, 15-18	

- 275 Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?. **2016**, 4, S31 0
- 274 Effect of Coadministration of Gastric Acid-suppressing Drugs on the Safety and Efficacy of EGFR-TKIs in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer. **2017**, 57, 190-195
- 273 EGFR Mutant. **2017**, 167-189
- 272 AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES. **2017**, 46-55
- 271 The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with T790M mutation to anti-EGFR drugs in non-small cell lung cancer. **2018**, 20, 10-18
- 270 Molecular Targeted Therapy of Lung Cancer. **2018**, 14, 177-179
- 269 The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790M mutation and their significance in clinical practice. **2018**, 5, 17-24
- 268 Targeted Agents and Immunotherapy. **2019**, 381-388
- 267 Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.. **2019**, 8, 736-751
- 266 Clinicopathological characteristics with , , genetic alternation and prognostic analysis of primary lymphoepithelioma-like carcinoma.. **2019**, 8, 2350-2356
- 265 Traitement des cancers bronchiques non ^petites cellules de stades avancs muts EGFR: quelle(s) squence(s) ?. **2019**, 11, 364-379
- 264 Neurological Complications of Targeted Therapies. **2020**, 341-363
- 263 Lung Cancer. **2020**, 13-30
- 262 Systemic Therapy of Brain Metastases: Lung Cancer. **2020**, 207-217
- 261 Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study. 1-1 0
- 260 Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. **2020**, 96, 266-272 2
- 259 Recomendaciones de onclogos que trabajan en el ISSSTE para el tratamiento sistmico del cncer de pulmñ avanzado 2020. **2020**, 2, 164-181
- 258 Adjuvant EGFR-TKIs-based therapy: are we ready?. **2020**, 9, 948-950

257	Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. 2021 , 6, 374	1
256	Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model. 2021 , 11, 721318	1
255	OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS. 2020 , 19, 119-125	
254	Aktuelle Entwicklungen in der personalisierten Therapie des metastasierten nichtkleinzelligen Lungenkarzinoms âUpdate. 2021 , 16, 8-16	
253	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. 2021 , 8, 1984375	
252	Dermatological Toxicities of Targeted Therapy. 2020 , 147-164	0
251	Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.	
250	Pulmonary Toxicities of Targeted Therapy. 2020 , 133-146	
249	Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. 2021 , 162, 154-161	4
248	Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIa (8th edition TNM classification) primary lung cancer after curative surgery. 2021 , 162, 128-134	0
247	Achievements in targeted therapies. 215-233	
246	Multi-state network meta-analysis of cause-specific survival data.	
245	Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. 2021 , 80, 100795	0
244	Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. 2015 , 7, 875-80	10
243	Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. 2015 , 4, 82-93	29
242	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. 2015 , 3, 81	9
241	EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. 2014 , 4, 411-35	96
240	Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. 2015 , 7, 217-9	

239	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. 2015 , 8, 3294-8	2
238	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. 2015 , 12, 126-39	19
237	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. 2015 , 8, 10330-9	16
236	Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapy. 2016 , 8, 116-23	1
235	The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. 2016 , 5, 106-9	5
234	Afatinib in Non-Small Cell Lung Cancer. 2015 , 6, 448-55	5
233	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. 2017 , 34, 405-408	0
232	Molecular Targets in Non-Small Cell Lung Cancer. 2017 , 17, 388-392	14
231	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. 2016 , 7, 723-735	4
230	[Efficacy and Toxicity of Metronomic Oral Vinorelbine in Advanced Non-small Cell Lung Cancer after Failure to Multiple-lines Treatments]. 2017 , 20, 737-740	2
229	[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer]. 2017 , 20, 61-65	1
228	[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. 2017 , 20, 617-622	3
227	[Driven Gene in Patients with Lung Squamous Cell Carcinoma: ?Analysis of Clinicopathologic Characteristics and Prognosis]. 2016 , 19, 648-652	1
226	[Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis]. 2016 , 19, 837-846	1
225	[Nimotuzumab significantly enhances chemosensitivity of PC9 human lung adenocarcinoma cells to paclitaxel in vitro]. 2015 , 18, 98-103	0
224	[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. 2015 , 18, 110-6	
223	[Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. 2015 , 18, 146-54	0
222	[TKI Resistance for T790M Mutation]. 2015 , 18, 245-50	1

221	[Treatment of advanced NSCLC with unknown EGFR gene status?--TKI or chemotherapy?]. 2014 , 17, 709-14	
220	Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung. 2017 , 8, 267-272	
219	Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. 2018 , 9, 189-200	11
218	[Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy ?in Advanced NSCLC Patients with EGFR Mutations]. 2019 , 22, 99-104	1
217	[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer?with Uncommon EGFR Mutations]. 2019 , 22, 590-599	0
216	[Clinical characteristics and risk factors affecting outcomes of elderly patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease]. 2017 , 37, 889-894	
215	Serum EGFR gene mutation status via second-generation sequencing and clinical features of patients with advanced lung cancer. 2018 , 11, 3551-3558	2
214	[Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer]. 2020 , 23, 710-718	
213	A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer. 2020 , 13, 3060-3082	2
212	Predicting mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. 2021 , 11, 546-560	6
211	[Comprehensive Treatment of An Advanced Lung Cancer Patient with ?EGFR Driver Gene Positive]. 2021 , 24, 447-452	
210	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant Brain Metastasis and Spinal Cord Metastasis Models. 2021 , 12, 750031	2
209	A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with Mutation-Positive Non-Small Cell Lung Cancer. 2021 , 13, 8695-8705	1
208	Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. 2021 , 155, 307-317	1
207	Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. 2021 , 12, 781084	
206	Identification of lncRNA-miRNA-mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor. 2021 , 12, 758591	2
205	First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. 2021 , 1	0
204	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. 2021 , 57,	0

203	Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of Amplification: Implications for Novel Personalized Therapy.. 2021 , 11, 750852	1
202	Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. 2021 ,	0
201	Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. 2021 , 12, 3407	2
200	Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis. 2021 , 23, 408-417	
199	Real-world experience of afatinib as first-line therapy for advanced mutation-positive non-small cell lung cancer in Korea.. 2021 , 10, 4353-4367	0
198	Indian subset analysis of a phase iiib open-label study of afatinib in epidermal growth factor receptor tyrosine kinase inhibitor-naïve patients with epidermal growth factor receptor mutation positive non-small cell lung cancer. 2021 , 5, 116	0
197	Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials.. 2021 , 11, 757456	0
196	Root Extract of Scutellaria Baicalensis Increases Gefitinib Sensitivity in H1975 Human Non-small Cell Lung Cancer Cells. 2021 , 35, 117-123	
195	Predictive value of TCR Vβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial.. 2022 , 7,	4
194	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).. 2022 ,	1
193	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. 2022 , 27,	5
192	Molecularly directed therapy of advanced/metastatic non-small cell lung cancer.	
191	Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study.. 2022 , 15, 637-644	0
190	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations.. 2022 , 12, 766066	0
189	Functions of lncRNA DUXAP8 in non-small cell lung cancer.. 2022 , 49, 2531	0
188	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.. 2022 , 17, 1-13	3
187	Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study.. 2022 , 31, 100526	
186	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.. 2022 , 14,	0

- 185 Thoughts and suggestions on the fact that dacomitinib reduction did not affect its efficacy in the Archer 1050 study.. **2022**, 0
- 184 Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with m+ non-small-cell lung cancer.. **2022**,
- 183 The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.. **2022**, 12, 843299 0
- 182 Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.. **2022**, 12, 2167 1
- 181 Effect of high quality nursing on alleviating negative emotions in patients with advanced lung cancer. **2021**, 13, 11958-11965
- 180 Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.. **2022**, 16, 11795549221080347 0
- 179 Non-Small Cell Lung Cancer in Older Adults with Frailty. **2022**, 319-339
- 178 Neurological complications of lung cancer. **2022**, 243-276
- 177 Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.. **2022**, 21, 15347354221086663 0
- 176 ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.. **2022**, 2
- 175 A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction.. **2022**, 297, 591 0
- 174 Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI.. **2022**, 14, 0
- 173 The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.. **2022**, 42, 221
- 172 Efficacy and safety of first-line therapies in -mutated advanced non-small-cell lung cancer: a network meta-analysis.. **2022**, 0
- 171 Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. **2022**, 21, 61 0
- 170 Metabolic complete tumor response in a patient with mutant non-small cell lung cancer treated with a reduced dose of afatinib.. **2022**, 50, 3000605211058864 1
- 169 Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.. **2022**, 14, 0
- 168 Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for -Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review.. **2022**, 15, 3405-3416 0

167	Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series.. 2022 , 12, 872225	0
166	ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression?. 2022 , 13, 13-21	0
165	Feasibility, Tolerance, and Quality of Life for Hypofractionation Versus Conventional Fractionation for Post-mastectomy Radiotherapy in Indian Patients.. 2022 , 14, e23497	
164	Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).. 2022 ,	3
163	Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.. 2022 ,	1
162	Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA-IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study.. 2022 , 8, 816018	
161	Distinct and Common Features of Numerical and Structural Chromosomal Instability across Different Cancer Types.. 2022 , 14,	1
160	Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.. 2022 , 1	2
159	Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis.. 2022 , 3, 100322	0
158	Real-world Safety and Efficacy of Consolidation Durvalumab after Chemoradiotherapy for Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.. 2021 ,	5
157	Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.. 2022 , 7, 100398	0
156	Novel targeted therapies for advanced non-small lung cancer.. 2022 ,	0
155	TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy.. 2022 , 12, 860563	4
154	The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.. 2022 ,	0
153	Drug-induced diarrhea associated with antineoplastic drugs. 2021 , 13, 5-18	
152	Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.. 2021 , 2021, 9311875	3
151	Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence.. 2021 , 2021, 8736288	1
150	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2

149	Lung adenocarcinoma: development of nomograms based on PET/CT images for prediction of epidermal growth factor receptor mutation status and subtypes.. 2021 , 43,	0
148	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. 2021 , 12, 750031	5
147	Exceptional response to afatinib in a patient with persistent G719A -mutant NSCLC.. 2022 , 11, LMT54	0
146	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.. 2022 , 12, 6367	1
145	Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).. 2022 ,	
144	EGFR signaling pathway as therapeutic target in human cancers.. 2022 ,	1
143	Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.. 2022 , 23,	0
142	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.. 2022 ,	7
141	CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.. 2022 ,	0
140	Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations.. 2022 ,	1
139	Table_1.DOCX. 2020 ,	
138	Data_Sheet_1.docx. 2019 ,	
137	Data_Sheet_2.docx. 2019 ,	
136	Data_Sheet_1.PDF. 2020 ,	
135	DataSheet_1.zip. 2020 ,	
134	Table_1.docx. 2020 ,	
133	Table_2.docx. 2020 ,	
132	Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial.. 2022 , 12, e775	1

131	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as it appears?. 2017 , 34, 405	2
130	Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.. 2022 , 1	1
129	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.. 2022 , 22, 514	1
128	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.. 2022 ,	
127	Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.. 2022 , 17, e0267362	0
126	The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation. 2022 , 12,	0
125	B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.. 2022 , 20, 159	1
124	Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. 2022 , 14, 2519	1
123	Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent & EGFR; T790M Mutated NSCLC: A Phase IIb Study.	
122	Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. 2022 , 14, 2744	1
121	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.	0
120	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. 2022 , 22,	
119	Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. 2022 ,	5
118	Perioperative targeted therapy for oncogene-driven NSCLC. 2022 ,	1
117	Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.	
116	Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.	
115	Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. 2022 ,	1
114	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. 2022 , 16, 117955492211032	0

113	Dual roles of drug or its metaboliteâprotein conjugate: Cutting-edge strategy of drug discovery using shotgun proteomics. 2022 , 42, 1704-1734	
112	Platelet Activation in High D-Dimer Plasma Plays a Role in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Mutant Lung Adenocarcinoma. 12,	
111	Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. 2022 , 11, 3366	1
110	Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.	1
109	Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.	0
108	Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. 2022 , 13, 897	
107	Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations. 2022 , 3, 100348	
106	Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. 2022 , 14, 3362	
105	Pozotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. 2022 , 40, 754-767.e6	4
104	Treating advanced lung cancer in older veterans with comorbid conditions and frailty. 2022 ,	
103	Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open-Label, 2-Period, Single-Dose Crossover Study.	
102	Emerging strategies to overcome resistance to third-generation EGFR inhibitors. 2022 , 15,	4
101	âSandwichâStrategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients. 12,	0
100	Circ-MAN1A2 Contributes to the Acquired Resistance of Gefitinib by Binding to miR-409-3p to Induce TWIST1 Expression in Non-small-cell Lung Cancer.	
99	Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase InhibitorsâIs NF1 Tumor Suppressor a Key Role in Acquired Resistance?. 2022 , 14, 3323	
98	Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. 2015 , 44, 449-462	2
97	Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation. 12,	0
96	Experience of lung cancer patients with targeted therapy-related skin adverse drug reactions: A qualitative study. 2022 , 100115	

- 95 Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis. **2022**, 177, 103760 1
- 94 The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare. **2022**, 14, 3511
- 93 AZD4625 is a potent and selective inhibitor of KRAS G12C.
- 92 A Case of Osimertinib-Induced Eosinophilic Pneumonia. **2022**, 0
- 91 L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. **2022**, 13, 0
- 90 Efficacy and safety of EGFR-TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations. 1
- 89 Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.
- 88 Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12, 0
- 87 EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022. 0
- 86 Knockdown of GSG2 inhibits the development and progression of non-small cell lung cancer in vitro and in vivo. 1-12
- 85 Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. **2022**, 0
- 84 Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation. 13,
- 83 Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. **2022**, 12, e062036
- 82 Translational Research in Lung Cancer. **2022**, 0
- 81 Targeted Therapies in Non-small Cell Lung Cancer. **2022**, 1
- 80 Nano-composite hydrogels of Cu-Apa micelles for anti-vasculogenic mimicry. 1-13 0
- 79 Optimization of Tokuhashi Scoring System to Improve Survival Prediction in Patients with Spinal Metastases. **2022**, 11, 5391 0
- 78 EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy. 0

- 77 Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. 12, 0
- 76 A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma. 0
- 75 Prognostic factors for relapse-free survival in stage IB-IIIa primary lung adenocarcinoma by epidermal growth factor receptor mutation status. **2022**, 22, 0
- 74 Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): clinical experience of the Galician Lung Cancer Group. **2022**, 100646 0
- 73 Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study. **2022**, 22, 1
- 72 First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. **2022**, 13, 204062232211257 0
- 71 Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations. **2022**, 16, 175346662211327 0
- 70 Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. **2022**, 251-267 0
- 69 New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. **2022**, 23, 1626-1644 1
- 68 Algorithm thérapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de lâEGFR. **2022**, 14, 25189-25208 0
- 67 Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study. **2022**, 0
- 66 Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. **2022**, 15, 1
- 65 TAS2940 , a Novel Brain-Penetrable Pan-ERBB Inhibitor, for Tumors with HER2 and EGFR Aberrations. 0
- 64 The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. **2022**, 17, e0275919 0
- 63 Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-9 0
- 62 Small molecule inhibitors targeting the cancers. **2022**, 3, 0
- 61 Nuclear Receptor and Stress Response Pathways Associated with Antineoplastic Agent-Induced Diarrhea. **2022**, 23, 12407 0
- 60 Cancer of the Lung. 1-29 0

- 59 Analyse de la prise en charge des cancers bronchiques avec mutation du gène de l'EGFR. **2022**, ○
- 58 Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation. **12**, ○
- 57 The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study. ○
- 56 The Glasgow prognostic score predicts survival in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations who are treated with tyrosine kinase inhibitors. ○
- 55 Absence of copy number gain of EGFR : A possible predictive marker of long-term response to afatinib. ○
- 54 A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. **2022**, **174**, 133-140 ○
- 53 Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer. **2022**, **21**, 153473542211443 ○
- 52 ASTRIS, estudio de mundo real con osimertinib en pacientes EGFR mutados, progresados con T790M. **2018**, **23**, ○
- 51 Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. **2022**, **22**, ○
- 50 The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis. **2022**, **24**, 340-344 ○
- 49 Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?. **2022**, **20**, ○
- 48 Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. ○
- 47 ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3ASCaspase 8 Signaling Pathway to Promote Resistance to Gefitinib. **2022**, **2022**, 1-16 ○
- 46 PROTAC therapy as a new targeted therapy for lung cancer. **2022**, ○
- 45 Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial. ○
- 44 The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR -mutated non-small cell lung cancer. ○
- 43 EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives. ○
- 42 Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study. **12**, ○

41	Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study. 2022 , 22,	o
40	Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes. 10,	o
39	Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea.	o
38	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. 2022 , 3,	o
37	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. 2022 , 15,	1
36	Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.	o
35	EGFR-Directed Therapy in Lung Cancer. 2023 ,	o
34	Negative impact of the microvascular area to tumor area ratio on the response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation.	o
33	Importancia del test de mutaci3n del receptor del factor de crecimiento epid3rmico en c3ncer de pulm3n de c3lulas no peque2as. 2015 , 20,	o
32	Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study. 2023 , 12, 236	o
31	Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report. 2023 , 24, 602	o
30	The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. 2022 , 12,	o
29	Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. 2023 , 15, 187	o
28	Negative impact of the microvascular area to tumor area ratio on the response to EGFR-TKI in NSCLC with EGFR mutation.	o
27	Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance. 2023 , 91, 103-119	o
26	Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study. 2023 , 15, 642	o
25	Multivariate analysis of prognostic factors in patients with lung cancer. 13,	o
24	Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study. 2023 , 185, 83-93	o

- 23 Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. **2023**, 15, 629 ○
- 22 Komplikatives Hämato mediastinum einer 76-jährigen Patientin nach Durchführung einer endosonografisch gesteuerten transbronchialen Kryobiopsie (EBUS-TBKB) bei Verdacht einer Lymphomerkrankung. **2023**, 77, 162-167 ○
- 21 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 20 Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition. **2023**, 15, 1092 ○
- 19 Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan. **2023**, 18, 195-207 ○
- 18 Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. ○
- 17 Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. **2023**, 8, ○
- 16 Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy. **2023**, 46, 505-510 ○
- 15 Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. **2023**, 43, 1-12 ○
- 14 Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy. **2023**, 23, ○
- 13 Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study. ○
- 12 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 11 Intelligent Genetic Decoding System Based on Nucleic Acid Isothermal Amplification for Non-Small Cell Lung Cancer Diagnosis. **2023**, 14, 647 ○
- 10 Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. **2023**, 15, 1766 ○
- 9 Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma. 13, ○
- 8 New targeted therapies for non-small cell lung cancer. **2023**, 66, 180-190 ○
- 7 Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). **2023**, 16, 534 ○
- 6 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14, ○

- 5 The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis. **2023**, 2023, 1-8
- 4 Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. 13,
- 3 Afatinib in Pediatric Patients With Recurrent/Refractory ErbB-dysregulated Tumors: Results of a Phase I/Expansion Trial. **2023**,
- 2 Targeted therapy. **2023**, 205-411
- 1 An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients.